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Summary.
In order to grow, a tumour must obtain a blood supply. This process is called 
angiogenesis. It is likely that the better a tumour is able to obtain a blood supply, the 
faster it may grow and the more access the cells o f the tumour may have to the 
circulation for haematogenous metastasis.
Several authors have reported that breast tumours that contain large numbers o f blood 
vessels have a poor prognosis. This suggests that angiogenesis is an important 
mediator o f the behaviour o f breast tumours.
A protein called vascular endothelial growth factor (VEGF) has been described which 
is a potent inducer of angiogenesis. It is a specific endothelial mitogen produced by 
both normal tissues and tumours.
Prior to commencement o f this thesis the role of VEGF in breast cancer had not been 
reported. Given the apparent importance o f vascularity to prognosis in breast cancer 
it was hypothesised that VEGF may be o f importance in the behaviour of these 
tumours.
The aim of this research was to develop and apply techniques for studying the 
expression o f VEGF in breast cancers. It was hoped that such techniques might be of  
value identifying a group o f patients whose prognosis was poorer than would be 
expected from conventional predictors such as lymph node status. This would allow 
the potential for intervention either with specific anti-angiogenic therapy or 
conventional adjuvant therapy.
A part of the cDNA sequence of VEGF was cloned into a plasmid expression vector. 
The vector was reproduced in bacterial cultures and the presence o f the cloned 
sequence verified by Southern blotting, PCR and DNA sequencing.
The vector was then used to produce an RNA riboprobe with a non-radioactive 
digoxigenin label. Attempts were made to use this probe and a DNA oligonucleotide
10
probe to seek VEGF RNA both by Northern blotting and by in situ hybridisation. 
These attempts were hampered by high levels o f non specific binding o f the probe.
Several antibodies against VEGF protein were tested to investigate the feasibility of 
identifying VEGF by immunohistochemisty. Despite the use o f antigen unmasking 
techniques, this proved unsuccessful with the tissue samples used.
A semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) based 
assay for studying the relative expression o f VEGF in breast tissue was developed and 
optimised. Amplification of p-actin mRNA was also carried out to control for the 
quantity and quality o f the mRNA in the tissue samples. A linear relationship between 
the amount o f mRNA samples and the amount o f amplified cDNA product after RT- 
PCR was verified. VEGF and p-actin mRNA concentrations in the tissue samples 
was compared to a standard RNA solution extracted from a breast cancer cell line 
(T47D).
It proved possible to use this assay to compare samples o f breast tumours and 
adjacent breast. Due to its inherent molecular amplification, this RT- PCR assay has 
the advantage of requiring very small amounts o f RNA and is therefore applicable to 
small samples o f archival material or clinical biopsies.
Relationships o f the expression o f VEGF to the pathological characteristics and 
clinical behaviour of the tumours were examined. No clear difference was seen 
between VEGF expression in tumours and adjacent breast though the numbers of 
tissue samples studied was not sufficiently large to draw conclusions regarding any 
link between VEGF and tumour behaviour.
Recently several authors have found evidence that VEGF is indeed important in breast 
cancer. The literature regarding this has been summarised in the introduction to this 
thesis.
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Chapter 1. Introduction
1.1 Tumour Angiogenesis
Angiogenesis is the process of formation o f new blood vessels. The term, derived 
from the Greek words angion (a vessel) and genesis (birth), was used by Judah 
Folkman [1] over thirty years ago to describe the mechanisms by which tumours 
obtain a blood supply. It has been the subject o f much research since then. Blood 
vessel formation starts in the third week o f foetal development and continues as a 
normal physiological event throughout life. It is a mechanism essential to growth and 
wound healing but also plays a part in many pathological processes including cancer.
The behaviour o f tumours placed in situations where they are not able to obtain a 
blood supply has been studied by implanting them, floating in suspension, in the 
anterior chamber o f the rabbit's eye [2]. In these situations, the size o f the tumour is 
limited by the capacity of the central cells to obtain nutrients by diffusion and 
generally does not exceed a few millimetres in diameter. By contrast it was observed 
that a tumour implanted in vascularised tissue grows rapidly and that tumours usually 
contain a large number of blood vessels. Thus, it was assumed that blood vessels grew 
into a tumour from the host vasculature. The methods initially used to study this 
process involved implanting tumours in chambers into the ears o f rabbits [3], or the 
cheek pouches of hamsters [4]. By enclosing tumours in chambers made from 
millipore filters, it could be demonstrated that the angiogenic response was mediated 
by small diffusible elements [5], The rabbit cornea or the chorioallantoic membrane of 
the chick egg [6,7] proved convenient sites since the development o f blood vessels 
could be continuously observed. Other substances could also be introduced to test 
their effect on the angiogenic process [8]. Observations made on these systems have 
led to a better understanding o f the cellular events o f the angiogenic response. The 
new vessels originate from small venules and existing capillaries and the 
neovascularisation process principally involves endothelial cells [2, 8]. The earliest 
event is the degradation of the capillary basement membrane under the influence of 
proteolytic enzymes produced by the endothelium [9]. Endothelial cells migrate out of
13
this breech and move towards the tumour. These cells form a column with most of the 
mitotic activity occurring a few millimetres behind the advancing tip. The column 
develops a lumen and loops o f these new capillaries form with blood flowing in them.
In 1971 Folkman's group [1] found that one fraction isolated by gel filtration from 
tumour cell extracts was angiogenic when introduced into a dorsal pouch on a rat. 
They called this fraction, which consisted o f carbohydrates, RNA and protein, tumour 
angiogenesis factor (TAF). Klagsbrun et al [10] purified an endothelial mitogen 
released by hepatoma cells and demonstrated that this was structurally similar to basic 
fibroblast growth factor (bFGF). Schweigerer et al [11] have shown that capillary 
endothelial cells secrete bFGF and are capable of autocrine stimulation. Some o f the 
factors which have been purified, such as that obtained by Keegan et al [12], are only 
effective in vitro if a collagen substrate is used. Thompson et al [13] found that 
plasmin digests o f fibrin were angiogenic in the chorioallantoic membrane assay while 
West et al [14] showed that fragments o f hyaluronic acid between four and twenty 
five disaccharides long were angiogenic in this assay. The production o f proteolytic 
enzymes by endothelial cells has been well documented [14, 15]. Gross et al [9] 
found that capillary endothelial cells in culture could produce low levels o f 
plasminogen activator and collagenase. This production could be stimulated by agents 
such as tissue plasminogen activator. If this activity could be stimulated by tumour 
products, there is a possibility o f a positive feedback loop o f endothelial cell 
stimulation.
A number o f growth factors have been documented which stimulate endothelial cells 
in vitro and are angiogenic in vivo. These include acidic and basic fibroblast growth 
factors, transforming growth factor-alpha, epidermal growth factor, platelet derived 
endothelial growth factor and the vascular endothelial growth family o f angiogenic 
peptides that will be discussed in depth later.
Whilst cells in a pre-vascular tumour may replicate as rapidly as those in a 
vascularised tumour, the generation of new cells is balanced by cell death. The switch 
to an angiogenic phenotype results from over expression o f an angiogenic protein, 
mobilisation o f an angiogenic protein from the extracellular matrix, recruitment of
14
host cells such as macrophages that produce angiogenic proteins or a combination of 
these factors. It also appears that the angiogenic phenotype depends on the decreased 
production o f inhibitors of angiogenesis such as thrombospondin-1, glioma derived 
angiogenesis inhibitor and angiostatin.
1.2 Angiogenesis in Breast Cancer.
The capacity o f tissues from the human breast to induce angiogenesis was 
demonstrated by Brem et al [16] in 1978. They found that some samples of normal 
breast tissue would generate an angiogenic response in the rabbit’s eye model. The 
response was stronger if the tissue was derived from a breast containing a tumour and 
stronger still if the cancer tissue, either in situ or invasive, was used. Jensen et al [17] 
subsequently confirmed that 15% of lobules from normal breasts gave rise to an 
angiogenic response compared to 28% of histologically apparently normal lobules 
from breasts containing ductal carcinomas.
Weidner [18] looked at the relationship between the number o f microvessels 
(capillaries and venules) in histological sections from breast carcinomas. Using 
immunostaining for factor VIII, he counted the number o f microvessels per high 
power field in the areas that appeared to be richest in these vessels. He found that 
tumours from patients with lymph node metastases had a significantly higher number 
of microvessels. There was a steady increase in the likelihood of lymph node 
metastasis with increasing vessel count. All fifteen tumours with greater than one 
hundred vessels per 200x field had lymph nodes involved compared to only one of 
seven patients with less than thirty three vessels. He also noted rings o f increased 
vascularity in the immediate vicinity o f ducts containing carcinomas in situ.
This work created considerable interest and many other groups performed similar 
studies.
In 1992, Bosari [19] confirmed that node-positive patients had tumours with a higher 
microvessel count. He also found that, within the node-negative group, patients who
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subsequently developed distant metastases had a significantly higher microvessel 
count than those who did not.
The following year, To et al [20] reported microvessel counts in tumours from 125 
patients with and without lymph node involvement by staining using both factor VIII 
and CD 31 antibodies. They found that in both node-positive and negative groups 
high microvessel density was an independent strong predictor o f poor relapse-free 
survival.
In 1994, Obermair et al [21] also found that tumours with greater than ten 
microvessels per 1mm2 ocular raster were associated with five year disease free 
survival o f 43% compared with 88% for those with less than ten. Whilst lymph node 
metastases were more common in the tumours with higher microvessel count, the 
effect of microvessel density on survival appeared to be an independently significant.
Horak et al [22] found an increased number o f microvessels in the majority o f breast 
cancers compared to normal breast. This had a strong correlation with lymph node 
metastases. Tumours with a high vascular count (above 160 microvessels /mm2) had 
an 86% incidence o f lymph node metastases compared with 15% of those with a low 
vascular count. Indeed, vascular count appeared to be more significant than the 
degree o f lymphatic infiltration in predicting lymph node metastases. An association 
was also seen between increased vascular count and poor three year survival.
In 1994, Gasparini and Weidner [23] examined a series o f potential prognostic 
markers in node-negative breast cancer patients including size, histological 
characteristics, p53 and erb B expression. In a series o f 254 patients, they found that 
high microvessel density (assessed by CD31 staining) was the best predictor of poor 
disease-free survival over six years o f follow up.
Van Hoef et al. [24] however found no association between tumour vascularity and 
disease free survival in a study of 93 node-negative patients. They used a graticule 
giving a smaller counting field than the previous authors but otherwise very similar 
methods.
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Hall et al in 1992 [25] also showed no association between microvessel counts and 
metastasis. However, although one group of thirty-seven patients in their study had 
been followed-up for a median 9.5 years, the remaining 50 patients had a median 
follow up o f only 1.5 years. Furthermore, for the analysis, the authors grouped 
together a heterogeneous group of patients with “metastasis”. These comprised those 
with lymph node involvement at the time o f surgery and those who developed either 
lymph node or distant metastasis on follow-up.
In 1995, Axelsson [26] reported a large study o f 220 patients with both node-positive 
and node-negative ductal carcinomas over a median follow up o f 11.5 years. They 
found that obtaining consistent results for microvessel counting was difficult with 
considerable variation between different areas o f a tumour and between different 
observers. They concluded that microvessel count did not predict for either relapse 
free or overall survival
There has been much discussion about improving the reproducibility o f vascular 
assessment. In 1943, Chalkley [27] described a method o f measuring the relative 
volumes of the component parts o f tissues by noting which part o f the tissue was 
superimposed on a graticule point. Hansen [28] found that Chakley counting yielded 
less observer variation than Weidner’s microvessel counting method.
Variations of this technique have been applied to the assessment o f tumour 
vascularity. Fox et al [29] used a technique involving superimposing a 25 point 
graticule on the area of apparent maximum vascularity and aligning it in such a way 
that the maximum number o f point overlay immunostained vessels or their lumens. 
This removes the random nature o f the point placement intrinsic to Chalkley’s 
method. They showed a significant association between high vessel count and both 
poor survival and an increased likelihood o f lymph node metastasis.
Vascularity can also be assessed by measurement of the cross sectional area o f tumour 
vessels by computerised image analysis and some studies have showed that this
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correlates better with prognosis breast carcinoma than microvessel counting and is 
less subject to observer variation [30],
1.3 Vascular Endothelial Growth Factor
In 1983 Senger [31] described a protein secreted by rodent tumour cell lines, which 
reversibly increased vascular permeability. He called this protein vascular 
permeability factor (VPF). Three years later [32], he reported that several cell lines 
derived from human tumours including bladder & cervical carcinomas and osteogenic 
sarcomas also produced this factor. He found that tumour-derived cell lines produced 
more o f this protein than cell lines derived from non-malignant tissues.
In 1989, Napoleone Ferrara [33] described a protein called vascular endothelial 
growth factor (VEGF) isolated from normal pituitary follicular cells. It had selective 
mitogenic activity for endothelial cells. The same year, Connelly [34] discovered that 
VPF was also a selective endothelial mitogen, stimulating thymidine incorporation in a 
bovine endothelial cell line but not in a range of other connective tissue cell lines. 
Later in 1989, Leung, working with Ferrara, published the cDNA sequence o f VEGF 
[35]. Almost simultaneously, Pamella Keck published the sequence of the VPF 
cDNA [36]. She initially commented on homologies between this sequence and the B 
chain o f platelet derived growth factor but added during proof that the sequence of 
VPF was the same as the VEGF sequence newly published by Ferrara’s group. It had 
become apparent that VPF and VEGF were products of the same gene.
VEGF is a dimeric glycoprotein composed o f two disulphide bonded polypeptide 
subunits. Five different polypeptide variants have been discovered. These have 
identical N  termini but showing variations in other regions. They arise by alternative 
splicing o f the transcript from a gene with eight exons [37] to produce polypeptides 
with 121, 145, 165, 189 and 206 amino acids. VEGF145 [39] has so far only been 
demonstrated in placenta and tumours o f the female reproductive tract. The action of 
VEGF on endothelial cells is mediated via transmembrane tyrosine kinase receptors.
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VEGF 121 does not bind to heparin. The other variants bind to heparin with an affinity 
that increases with molecular weight. VEGF189 and VEGF206 are secreted but are 
almost completely bound to proteoglycans containing heparan sulphate in the 
extracellular matrix [40].
Keyt and his colleagues at Genentec [41] discovered that plasmin cleaves a 110 
amino acid fragment from VEGF165 bound to extracellular matrix. This fragment, 
which is devoid o f the heparin-binding domain, binds to the KDR (VEGF-II) receptor 
with a similar affinity to VEGF121 and VEGF165 in the absence o f heparin. Addition of  
heparin however potentiates the binding o f VEGF165 to KDR by 3-4 fold. The 110 
and 121 amino acid forms bind the FTL-1 (VEGF-1) receptor with up to twenty times 
less affinity VEGFi65 and this is not affected by heparin. The mitogenic potency of the 
110 and 121 forms is over a hundred-fold less than VEGF165.
Several growth factors and cytokines induce transcription o f VEGF RNA. These 
include platelet-derived growth factor-BB, epidermal growth factor, tumour necrosis 
factor alpha, transforming growth factor pi and interleucin ip  [42] and it therefore 
appears that some agents with angiogenic activity may work via there ability to 
promote VEGF production.
Having observed that tumour cells in necrotic areas of gliomas appeared to express 
high levels o f VEGF RNA, Shweiki et al [43] investigated the effect o f exposing lines 
o f benign and malignant cells to hypoxic conditions. They found that cells grown in 
hypoxic conditions showed upregulation o f VEGF RNA, which was reversed by 
introducing oxygen. Subsequent studies have shown that there is both increased 
transcription and stabilisation o f the VEGF RNA in hypoxic conditions.
Levy et al [43] showed that in rat phaeochromocytoma cells, hypoxia increased the 
VEGF mRNA transcription rate by three per cent but the steady state concentration 
o f VEGF mRNA increased by twelve percent. This suggests that the most important 
influence on the increase is post-transcriptional stabilisation o f the mRNA. They 
subsequently found [45] that in hypoxic conditions, the half-life o f VEGF mRNA in 
these cells increased from 43 to 106 minutes. VEGF mRNA in common with other
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unstable mRNA s has an area rich in adenine and uracil bases called A-U rich elements 
(AREs). In particular an AUUUA pentamer, in the 3’ untranslated region appears to 
be important. Levy’s group found that this area in VEGF formed protein-RNA 
complexes in hypoxia. They found [46] that in a human cell line hypoxia increased 
the half-life o f VEGF RNA from 4.8 to 8 hours. They used transformed versions of 
these cells that did not express the 36KDa RNA binding protein HuR and concluded 
that this protein was necessary for the hypoxia-induced stabilisation o f VEGF RNA. 
However, HuR is not overexpressed in hypoxic cells and is probably only one 
component o f the stabilisation. Shih and Claffey [47] discovered that in hypoxic cells, 
heterogeneous nuclear ribonucleoprotein L (hnRNP L) formed a complex with a 
hypoxia stability region in the 3’ untranslated region o f VEGF RNA. This region was 
juxtaposed to the ARE region and the authors suggested that binding hnRNP L may 
prevent the binding proteins such as hnRNP C to this region which are believed to 
destabilise mRNA. They found that in hypoxic cells there is a slight increase in 
hnRNP L whilst cytoplasmic levels of hnRNP C fall.
Several endothelial growth factors with high levels o f homology to VEGF, encoded 
by different genes, have recently been identified [42,48,49]. VEGF-B exists as two 
alternatively spliced forms with 167 and 186 amino acid subunits and can form 
heterodimers with VEGF. It is most abundant in heart and skeletal muscle. It 
appears to stimulate the release of both urokinase type plasminogen activator (uPA) 
and plasminogen activator inhibitor 1 by endothelial cells. Placental growth factor 
(P1GF) is a similar protein with angiogenic activity. Originally cloned from human 
placenta, it has subsequently been found in other tissues including thyroid and lung. It 
has two splice variants P1GF 1 (129 amino acids) and P1GF 2 (152 amino acids). P1GF 
also appears to be able form heterodimers with VEGF though these are less mitogenic 
for endothelium than VEGF homodimers. VEGF C and D show lower levels of 
homology (about 30%). They are found at low levels in heart and intestine and 
appear to be angiogenic. Cao et al [50] found that VEGF-C was a potent inducer of 
angiogenesis in mouse corneal micropockets and chick chorioallantoic membrane. A 
gene encoding a polypeptide with a 25% amino acid homology to VEGF has been 
found in the genome of the Orf virus. It has been called VEGF E [51]. It binds to the
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Flk-1 (VEGFR-2) receptor but not to the Flt-1 (VEGFR-1) receptor. Despite having 
no heparin-binding region, it has similar potency in inducing endothelial proliferation 
and vascular permeability as VEGF165. Salven et al [52] studied a range o f human 
tumours including breast and skin tumours. They demonstrated VEGF B in 90% and 
VEGF C in about 50%
The members o f the VEGF family are regulated by different stimuli [42, 49]. Growth 
factors such as TGF-p and cytokines increase expression o f VEGF and VEGF-C 
mRNA but do not affect VEGF-B. Amplification o f the ras oncogene, mutation o f the 
p53 tumour suppressor gene and hypoxia both upregulate VEGF expression but not 
VEGF B or C
The VEGF family peptides bind to a group o f three receptors called VEGFR-1 (Flt- 
1), VEGFR-2 (KDR/Flk-1) and VEGFR-3 (FLT-4) [42, 53]. All three comprise a 
seven segment immunoglobulin-like domain linked to a tyrosine kinase. VEGFR 1 
and 2 are found on endothelial cells whilst VEGFR-3 is found on lymphatic 
endothelium.
VEGFR-1 binds VEGF, VEGF-B and P1GF. VEGFR-2 binds VEGF, VEGF-C and 
VEGF-D whilst VEGFR-3 binds VEGF-C and VEGF-D. Cao’s group [50] found 
that VEGF-C was capable o f inducing proliferation and chemotaxis o f vascular 
endothelial cells via both VEGFR-2 and VEGFR-3. VEGFR-3 is not normally 
expressed on adult vascular endothelium but has been demonstrated on a cell line 
derived from umbilical vein [54], Expression o f the VEGFR-3 receptor is increased in 
some tumours and in lymph nodes containing metastases. It has been suggested that 
the VEGFR-1 receptor may be important for mediating endothelial survival whilst 
VEGFR-2 mediates angiogenesis. A mutation that prevents VEGFR-2 expression in 
nude mice prevents tumour growth and this receptor appears to be essential for 
tumour angiogenesis. Bematchez et al [55] studied the effect o f suppressing both Flt- 
1 and Flk-1 by treating endothelial cells in vitro with antisense oligonuclotides 
complementary to the mRNA coding for the two receptors. They found that 
inhibition o f Flk-1 (VEGFR-2) almost eliminated the stimulation o f proliferation, 
migration and production of platelet activating factor (PAF) by VEGF. They had
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previously demonstrated that the action o f VEGF on vascular permeability was 
mediated through PAF synthesis. Some production of PAF was observed when 
endothelial cells were stimulated by P1GF, which is a specific Flt-1 (VEGFR-1) 
agonist. This suggested that simulation o f this receptor also plays some part in the 
induction o f vascular permeability.
Hypoxia appears to directly upregulate VEGFR-1. Increased expression of VEGF 
appears to lead to upregulation of both VEGFR-1 and VEGFR-2 whilst exposure of 
cells to TNF-a increases VEGFR-2 expression.
Yonekura et al [56] have shown that endothelial cells produce VEGF, VEGF-B, 
VEGF-C and P1GF creating a potential autocrine loop o f endothelial stimulation.
Kaposi’s sarcoma cells have been found to express both VEGFR-2 [57] and VEGFR- 
3 [54] and to produce both VEGF and VEGF-C. This has been shown to give rise to 
autocrine stimulation o f tumour growth by both these members o f the VEGF family. 
More recently Dias et al [58] showed that VEGFR-2 was present in leukaemic cells 
from five out o f ten samples o f peripheral blood from patients with acute leukaemia 
and two out o f three leukaemic cell lines. Eight out o f ten o f the leukaemia cell 
samples also expressed VEGFR-1. All the patient samples and cell lines produced 
VEGF. Exogenous VEGFi65 increased leukaemic cell proliferation and migration 
whilst monoclonal antibody against VEGFR-2 inhibited leukaemic cells in vitro and 
improved survival in xenografted mice. VEFG and VEGF-C appear to act as 
autocrine growth factors in leukaemia.
1.4 VEGF in Cancer
Shortly after the discovery o f VEGF, it was found that some tumours appeared to 
produce more VEGF than their tissues o f origin. In 1992 two groups found that those 
central nervous system tumours associated with a high degree o f neovascularisation 
and oedema such as glioblastomas, meningiomas and capillary haemangioblatomas 
commonly produced higher levels o f VEGF than normal brain [59, 60]. Berger [61] 
examined VEGF expression by Northern blotting in 65 human tumours that had been 
xenografted into mice. Expression o f VEGF varied considerably even between
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tumours o f the same histology with some producing high levels and others not 
producing any detectable VEGF. Only three samples of normal tissues were however 
included making valid comparisons between tumour and normal tissues difficult. 
Subsequently there has been great interest in the significance o f VEGF expression to 
the behaviour and prognosis o f different forms of cancer.
Following the early discovery by Brown et al [62] that VEGF was expressed by 
normal kidney, the same group went on to show, by in situ hybridisation, that 11 out 
of 12 renal cell carcinomas expressed high levels o f VEGF [63], They also found high 
levels of VEGF RNA staining in three transitional cell carcinoma o f the bladder. 
Tominisawa et al [64] examined the significance of VEGF expression in renal cell 
carcinomas in more detail. They found by Northern blotting that VEGF RNA, 
especially the 189 splice variant, was overexpressed in the tumours compared to the 
surrounding tissues. Liu et al [65] examined expression o f VEGF and the KDR 
receptor in fifteen cell lines derived from a variety o f human tumour including breast, 
colon ovary, cervix and melanoma. All showed expression o f VEGF RNA by RT 
PCR but the three melanoma cell lines were unusual in also showing expression of 
KDR (VEGFR-2) giving the potential for autocrine stimulation. They confirmed this 
potential by demonstrating increased proliferation of the three melanoma cell lines in 
response to exogenous VEGF.
It was discovered that, as well as being overexpressed in tumour tissues, VEGF could 
also be found in the raised levels in the serum of tumour-bearing animals and of 
cancer patients. In 1993, Kondo et al [66] grafted both HeLa/v5 a cell line that 
produces high levels of VEGF and HeLa/c, a line that does not produce VEGF into 
nude mice. Prior to transplantation, no VEGF could be detected in the mouse serum 
but after transplantation VEGF could be detected in the serum of those transplanted 
with HeLa/v5 by enzyme linked immunosorbent assay (ELISA). They went on to 
show that whilst only very low levels o f VEGF were detectable in the serum of 
healthy subjects, significantly higher levels were found in serum derived from patients 
with uterine, cervical, ovarian and lung cancers.
23
Dirix et al [67] measured the serum levels o f VEGF by ELISA in a variety o f cancer 
patients. They compared these to the control group described by the manufacturers 
of the kit (R&D) but they had no local controls. Five out of fourteen patients with 
operable colonic cancer had serum levels above the 95th centile o f the reference group. 
Whilst the mean serum concentration o f VEGF decreased slightly with tumour 
resection, this was not statistically significant. They investigated patients with a 
variety o f metastatic carcinomas, breast, colorectal, ovarian & renal, and found that 
40% had serum levels above the 95th centile o f the manufacturer’s reference group. 
There most striking finding was however that 63% of patients with rapidly 
progressive cancer had a raised VEGF level compared to only 13% with slowly 
progressive disease.
The rather small differences between normal subjects and controls in this study may at 
least in part be explained by the discovery by Webb et al [68] that large amounts of 
VEGF were released into the serum when plasma clotted. The amount released 
varied considerably between samples. The concluded therefore that plasma rather 
than serum was the preferred medium for measuring circulating VEGF.
This finding was confirmed by Hyodo et al [69] who found high and variable levels of 
VEGF in serum from normal subjects by ELISA. They found that most patients with 
either gastric or colonic cancer had higher plasma levels o f VEGF than their normal 
controls. They found that a subset o f patients with metastases (38% of those with 
metastatic gastric cancer and 50% of those with colorectal cancer) had VEGF levels 
above the 95th centile of the levels in patients without metastases. This group showed 
shorter survival and a poorer response to chemotherapy.
Ishigami et al [70] compared the ratio o f VEGF mRNA expression in colorectal 
cancers and adjacent bowel (T/N ratio) by Northern blotting. They found that the 
presence o f liver or lymph node metastasis was associated with a significantly higher 
VEGF T/N ratio. They found that a high VEGF T/N ratio was an independent 
indicator o f increased risk o f death from tumour recurrence with a greater hazard 
ratio than tumour size, depth o f infiltration or degree o f differentiation.
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Landriscina et al [71] also found that the amount of VEGF, measured by ELISA, was 
higher in colorectal cancers than uninvolved mucosa. The same was not true o f the 
angiogenic factor bFGF although raised levels of both factors were found in 
mesenteric blood at the time of surgery.
Uchida et al [72] found that 60% of oesophageal cancers showed 
immunohistochemical staining for VEGF. There was a significant association of  
VEGF positivity with both advanced tumour stage and short survival.
1.5 Therapeutic Implications of VEGF in Cancer
Several clinical trials o f anti-angiogenic drugs are in progress [73], The main 
strategies currently being investigated are as follows.
■ Blockage o f endothelial cell proteases preventing breakdown of the surrounding 
matrix.
■ Direct inhibition of endothelial cells
■ Blockage o f the activities of specific factors that stimulate angiogenesis
■ Blockage o f the action of integrin on the endothelial cell surface
Given the importance of VEGF in angiogenesis, it is not surprising that attention has 
been given to agents that may block VEGF action. Several VEGF receptor inhibitors 
have been developed. SU5416 [74] is a 3-substituted indolinone that binds to 
VEGFR-2. It is currently undergoing phase III trials for metastatic colorectal cancer 
and in phase I and II trials [75] for many other tumours including advanced breast 
cancer. A similar substance, SU6668 [74], inhibits VEGFR-2 and also the PDGF and 
FGF receptors. It is currently undergoing phase I clinical trials. Several other receptor 
inhibitors have recently been developed including a series o f substituted 4- 
anilinoquinazolines which are potent inhibitors o f both VEGFR-1 and VEGFR-2 that 
are active by oral administration [74], Piossek et al [76] described a peptide derived 
from the third Ig-like domain of VEGFR-2 that blocked binding o f VEGFi65.
25
Monoclonal antibody against VEGF is currently undergoing phase I trials in refractory 
solid tumours and has reached phase II trials in metastatic renal cell carcinoma. 
Antibodies against the VEGF-2 receptor have also been developed.
1.6 VEGF in Breast Cancer
In 1994, Toi and his colleagues at Tokyo Komagone Hospital [77] investigated 
whether there was a link between the emerging evidence o f that increased microvessel 
density was an indicator of poor prognosis and the expression by these tumours of 
VEGF. They carried out immunoperoxidase staining o f breast cancer sections using 
FVIII related antibody and an anti-VEGF monoclonal antibody developed by 
Genentec. They graded VEGF staining as negative, moderate or high. Their initial 
study o f 103 primary breast cancer patients with 51 months follow up confirmed that 
microvessel density correlated inversely with relapse-free survival. They showed a 
significant link between VEGF and microvessel density and found that VEGF 
expression had an independent prognostic significance for disease-free survival on 
multivariant analysis. The following year, the same group published a larger study 
[78], using the same methodology, involving 328 patients with 56 months follow up. 
They still found that microvessel density was an independent predictor o f poor 
relapse-free survival. Whilst there was still a significant association between VEGF 
expression and poor relapse-free survival on univariant analysis, this did not prove to 
be independent on multivariant analysis.
In 1995 Brown et al [79] reported their results o f in situ hybridisation in breast 
tumours using a riboprobe to the common region of VEGF mRNA. They found that 
normal breast tissues from both reduction mammoplasties and breasts which had 
contained tumours stained weakly while 12 specimens o f ductal carcinomas and 4 
specimens o f comedo ductal carcinoma in situ (DCIS) stained strongly. Two 
specimens o f lobular carcinoma did not show any staining. They also found that 
endothelial cells adjacent to areas o f strong VEGF expression in both tumours and 
DCIS stained strongly for both the KDR (VEGFR-1) and ftl-1 (VEGFR-2) receptors.
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In 1996, Anan et al [80] found by RT- PCR that VEGFm and VEGF165 were both 
expressed in only 17% of benign breast samples whilst VEGF121 was expressed in 
84% of breast tumours and VEGF165 in 78%. TGF-a and bFGF were expressed in 
almost all o f the samples of both tumour and benign breast. They also found 
significantly more VEGF expression in the group of tumours with a high microvessel 
count than in the group with a low count.
By 1996 [81] Toy and the Tokyo group had succeeded in measuring VEGF protein 
levels in breast tumours by ELISA. They showed a considerable variation in protein 
levels in the 135 breast cancers examined. These ranged from 3.3 to 2032 pg per mg 
o f protein. There was a significant correlation between the intratumoural VEGF 
concentration and the microvessel density in the tumours.
The following year saw the start of a rush o f publications looking at VEGF in breast 
cancer. Gasparini [82] in Vincenza collaborated with the Tokyo group in studying 
VEGF protein concentrations in cytosolic extracts from tumours obtained from 260 
women with node-negative breast cancer who had a median period o f follow up of 66 
months. Postoperative radiotherapy was given where appropriate but they received no 
other adjuvant therapy. Again, there was a considerable range o f VEGF levels from 5 
to 6523pg per mg of protein. They found that, on multivariant analysis, there was a 
significant association between VEGF levels and both disease free and overall 
survival. This was independent o f other factors such as age, menopausal status, 
tumour size, histological type or hormone receptor status. The same year, in Oxford, 
Relf [83] described expression o f a range o f angiogenic factors, including VEGF in 35 
node-negative and 29 node-positive tumours. VEGF expression was measured using 
an RNAase protection assay. High VEGF expression correlated with a high risk of 
tumour recurrence on univariant analysis.
Obermair [84] in Vienna studied 89 patients with breast cancer (28 o f which were 
node-positive) treated by either mastectomy or local excision. Patients undergoing 
local excision had postoperative radiotherapy. Oestrogen or progesterone receptor 
positive patients received tamoxifen whilst receptor-negative patients received CMF
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chemotherapy. Three patients developed local recurrences and fourteen developed 
distant recurrences. They measured VEGF in tumour cytosols using the same ELISA 
technique used by the previous authors. Whilst confirming the previously described 
association between high VEGF concentrations and microvessel density, they failed to 
find a significant association between VEGF and relapse-free survival.
Two papers published the same year suggested that VEGF might be important in the 
early development o f breast tumours. Guidi et al [85] found that the tumour cells in 
ductal carcinoma in situ o f the breast stained more strongly than the surrounding 
breast epithelium by in situ hybridisation using a probe for VEGF mRNA. Yoshiji et 
al [86] at the National Cancer Institute reported a model system using subcutaneously 
implanted T47D tumour cells with VEGF expression controlled by a tetracycline 
regulated retroviral vector system. They found that suppression o f VEGF production 
strongly inhibited tumour growth in small tumours but did not do so once the tumours 
were large. In the larger tumours, basic fibroblast growth factor (bFGF) and 
transforming growth factor alpha (TGFa) appeared to be able to take over from 
VEGF
Anan’s group [87, 88] described the use of a semi-quantitative RT-PCR based assay 
to measure VEGF in breast cancers compared to actin, which was amplified in 
separate reactions. PCR products were measured by Southern Blotting or computer 
analysis o f gel photographs. They found a close correlation between VEGF 
expression measured in fine needle aspirates from tumours with the expression 
measured in the tumours after resection. There was a significant correlation between 
vascular counts and VEGF expression in forty eight ductal carcinomas but not in the 
small group of non-ductal (mucinous, medullary and lobular) carcinomas.
In 1998 two groups simultaneously published studies looking at the significance of 
VEGF in node-negative breast cancer. Linderholm [89] studied 525 consecutive 
patients o f whom 500 received no systemic treatment. Cytosolic VEGFi65 protein 
was measured by ELISA. VEGF was a significant indicator o f poor overall survival 
both when analysed as a continuous variable or divided into groups above and below
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the median value o f 2.40 pg/pg of DNA. The relative risk of a cytosolic VEGF 
higher than the mean was greater than that o f tumour size, grade, type or hormone 
receptor status. This was also the case when analysis was limited to the patients who 
did not receive any systemic treatment or to the patients who were oestrogen receptor 
positive. Eppenberger [90] described the analysis o f VEGF, bFGF, angiogenin, 
urokinase type plasminogen activator (uPA) and plasminogen activator inhibitor 1 
(PAI-1) in two patient populations. One was a heterogeneous set o f 305 patients, 
both node-negative and positive, from their own institution undergoing surgery 
between 1992-93 with a median follow up o f 36 months. The second population 
consisted o f a group o f node-negative patients operated on in another institution 
between 1978 and 1988 who had received no adjuvant treatment. This group had a 
median follow up of 76 months. Cytosolic VEGF protein levels were measured using 
a chemiluminescence immunosorbent assay. They grouped the tumours into those 
above and below the first quartile o f VEGF protein levels and found that the group 
with higher levels of VEGF had a significantly higher chance o f disease recurrence in 
both populations.
Lee at Guys hospital [91] used in situ hybridisation to study the proportion of tumour 
cells staining for VEGF in ductal and lobular carcinomas and correlated this with the 
microvessel count from the three most vascular fields in the tumour. They confirmed 
the results reported by Brown three years earlier that VEGF was expressed more 
strongly in ductal than lobular cancers. Nine out o f eleven ductal cancers showed 
moderate or strong expression whilst the remaining two showed weak expression. 
Eight out o f nine lobular cancers showed absent or weak expression with one showing 
moderate expression. As in the previous study, the majority of tissue samples of 
ductal carcinoma in situ showed strong or moderate staining. These results were 
confirmed by the staining patterns for VEGF on the sections by 
immunohistochemistry with both monoclonal and polyclonal antibodies. Microvessel 
density was slightly higher in the ductal carcinomas than the lobular carcinomas. 
Correlation was seen between VEGF expression and microvessel density in the ductal 
but not in the lobular carcinomas. The authors conclude that VEGF is an important
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mediator of angiogenesis in ductal carcinoma but that angiogenesis may be mediated 
by other factors in lobular carcinoma.
Given the emerging evidence regarding the importance of VEGF, Heer et al in Hull 
[92] looked at serum VEGF concentrations throughout the menstrual cycle and 
speculated on the implications of these for the timing of surgery. They measured 
serum VEGF by ELISA in 14 healthy premenopausal subjects along with FSH 
oestodiol and progesterone. The use of measurements in serum is questionable in the 
light o f previously described work [68, 69]. They found that VEGF concentrations 
were significantly lower in the luteal phase and showed a negative correlation with 
progesterone. They exposed the MCF7 breast cancer cell line to luteal phase serum 
from one subject and found a reduction in VEGF production. This however contrasts 
with the work o f Hyder [93] earlier the same year. He found that progesterone in 
physiological concentrations caused an increase in up to four fold in VEGF 
production in the T47D cell line, which is a strong expresser o f the progesterone 
receptor. Progesterone did not have any effect on VEGF production in several other 
cell lines, including MCF7, that show lower levels o f progesterone receptor 
expression. The significance of background VEGF production rather than tumour 
production is not known and the significance of varying serum levels in health subjects 
must be regarded as speculative A subsequent study by Mcllhenny in Glasgow did 
not show any variation o f VEGF with the menstrual cycle in health volunteers and no 
correlation with FSH or LH levels [121].
Linderholm et al published a further paper in 1999 [94] looking at a homogeneous 
group o f T1-2 node-negative tumours treated by local excision with radiotherapy but 
no systemic treatment. They studied 302 patients with a median follow up o f 56 
months o f whom 43 developed recurrent disease. Cytosolic VEGF was measured by 
the same ELISA method that they had used in their previous studies. Again, they 
found that patient with high VEGF levels had significantly shorter relapse free and 
overall survival. The relative risk o f high VEGF expression was even more 
pronounced when analysis was confined to the smaller T1 tumours. The authors
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suggest that in the tumours that would normally have a good prognosis, high VEGF 
expression was negating the protection normally conferred by radiotherapy. 
Therefore, high VEGF expression might be considered as a risk factor indicating the 
need for systemic therapy when this might otherwise not be deemed necessary.
The same year Gasparini’s group [95] published a study o f cytosolic VEGF protein 
concentration in two groups o f node-positive patients. One group o f 137 patients 
were treated with adjuvant CMF chemotherapy whilst the other group o f 164 were 
treated with tamoxifen, with a median follow-up o f 72 months in both groups. 
Cytosolic VEGF concentration proved to be a significant indicator o f poor relapse- 
free and overall survival on univariant analysis and a significant independent adverse 
prognostic indicator for both recurrence and survival on multivariant analysis.
Balsari and collaborators in Milan [96] published an analysis o f 36 heterogeneous 
patients with stage 1-3 breast cancer. They assessed VEGF production by a 
subjective assessment o f immunohistochemical staining. Their results supported the 
association between VEGF production and microvessel density. They did not find a 
significant correlation between serum VEGF concentrations and either VEGF staining 
in the tumours or microvessel density. This is, however, not surprising in view o f the 
previous studies showing the unreliable nature o f serum measurements.
Two papers published in 1999 looked at hormonal influences in VEGF production. 
Ruohala et al [97] looked at the influence on expression o f the VEGF family of 
growth factors o f exposing breast cancer cell lines to oestrodiol and antioestrogens in 
vitro. They measured VEGF RNA by Northern blotting and VEGF protein by 
ELISA. They found that oestodiol promoted production & stability o f VEGF mRNA 
and increased VEGF protein production in an oestrogen-sensitive MCF7 cell line. 
Whilst one oestrogen receptor blocker abolished this effect, tamoxifen and toremifene 
induced VEGF mRNA expression. VEGF-B levels were not affected by the addition 
of oestodiol whilst those o f VEGF-C were reduced. Greb et al [98] attempted to 
look at the effect o f ovarian hormones on VEGF mRNA in human breast in vivo by 
comparing tissue samples o f both neoplastic and adjacent non-neoplastic breast from 
premenopausal and postmenopausal women. They used a quantitative RT-PCR based
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assay using GAPDH primers in the same tube as the VEGF reaction. They found that 
in the non-neoplastic tissues VEGF mRNA expression decreased with age and was 
significantly lower in the postmenopausal women. There was however, no significant 
difference in VEGF mRNA expression in the tumour samples from the premenopausal 
and postmenopausal women. Indeed there was a slight, though not significant, 
increase in tumour VEGF mRNA levels with age. Of the nineteen women studied, 15 
had oestrogen receptor positive tumours and 14 had progesterone receptor positive 
tumours. The assumption that the decrease o f VEGF mRNA in the non-neoplastic 
tissues in this study is hormonally mediated is unproven. It could be hypothesised 
that it was due to some other non-hormonal effect o f tissue ageing. The authors also 
admit that the results in tumours may be questionable since GAPDH may be 
upregulated in some breast tumours.
The effects o f tamoxifen on VEGF production were explored further the following 
year by Adams et al. [99]. They confirmed the previous work regarding the 
advantage o f plasma over serum measurements. Neither o f these measures however 
correlated with an assessment of VEGF immunostaining on tumour tissue sections. 
Plasma levels o f VEGF were higher in patients being treated with tamoxifen. Since the 
tumours had been removed however, the source o f VEGF was unknown and the 
authors suggested it may arise form uterine tissue. Oestrogen receptor expression in 
the tumours was associated with stronger VEGF immunostaining.
Linderholm’s [100] group added to their previous work on node-negative tumours 
with a study examining VEGF in a series o f 362 node-positive tumours. They 
measured cytosolic VEGF protein by ELISA as in their previous study. They did not 
find a significant difference in VEGF concentration between these node positive 
patients and node negative series they had previously studied [94]. In contrast to 
Adams [99], they found significant inverse association between oestrogen receptor 
and VEGF expression. As with the node-negative patients, high VEGF expression 
was an independent predictor o f poor overall survival and a predictor o f poor relapse- 
free survival. High VEGF expression predicted poor overall survival in patients 
receiving both endocrine therapy and chemotherapy. It predicted poor relapse-free
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survival in patients receiving endocrine therapy but not in those receiving 
chemotherapy. This group has published a further study [101] examining the 
relationship between mutation in the p53 tumour suppresser gene and VEGF 
expression in 485 node-negative and 348 node-positive patients with breast cancer. 
They used a commercial ELISA kit that claimed to detect mutant but not wild type 
p53 and measured cytosolic VEGF by ELISA as in their previous studies. They 
found a statistically significant association between expression o f mutant p53 and high 
VEGF expression. Sixty four percent o f patients with mutant p53 had increased 
VEGF expression whereas only 43 percent o f patients without mutant p53 had raised 
VEGF concentrations. Both raised VEGF and mutant p53 expression predicted poor 
relapse-free and overall survival except in a small subgroup o f 25 high-risk patients 
receiving CMF chemotherapy. It is not clear whether the failure o f VEFG to be a 
significant predictor o f outcome in this group was due to the chemotherapy or purely 
a reflection o f the small size of this subgroup.
The role o f other members o f other members o f the VEGF family in breast cancer has 
been investigated. Gunningham et al [102] found that whilst there was no significant 
difference in VEGF-B expression between normal breast and breast tumours, there 
was a significant association between expression o f this protein and the number of 
involved lymph nodes in breast cancers.
Evidence has begun to emerge that VEGF is probably an important predictor of a 
group o f patients at high risk o f tumour relapse. The ability to identify these patients 
allows the possibility for intervention. This may take the form either o f more 
aggressive use o f adjuvant therapy than would normally be indicated from 
conventional prognostic indicators such as node status or the employment o f specific 
anti-angiogenic agents as described. It remains to be seen whether the ability to 
identify this group o f patients will ultimately improve their outcome.
1.7 Purpose of the Present Study
When this study was commenced, VEGF expression had been demonstrated in a small 
number o f tissues using immunohistochemistry or in-situ hybridisation. There had
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been no published accounts o f VEGF expression in breast tumours. As has been 
described, there was evidence that the amount o f neovascularisation within breast 
tumours may be of considerable prognostic importance. Estimation of 
neovascularisation by examination o f histological sections is a laborious process 
subject to observer variation and requiring fairly large tissue samples. A molecular 
marker o f the angiogenic potential of the tissue would therefore be valuable. The 
evidence which had emerged in the proceeding few years suggested that VEGF had 
great potential as such a marker.
A technique for measuring VEGF which was rapidly quantifiable was needed. It was 
intended that this technique could be used with small samples o f archival breast 
tumours. If VEGF proved to be o f prognostic significance that the technique could 
be applied to very small biopsy samples, and fine needle aspirates. A fundamental 
requirement o f the assay technique was that it should be provide sensitive detection of 
VEGF in the smallest possible samples.
The more established techniques of in situ hybridisation and immunohistochemistry 
were explored, primarily because these had the advantage o f allowing localisation of 
VEGF production in the case o f in situ hybridisation and tissues localisation of the 
protein with immunohistochemistry. The main part o f this work however consisted 
of the development o f an assay for VEGF based on the technique of the polymerase 
chain reaction. Intrinsic to this technique is the amplification o f the nucleic acid 
species being investigated making it extremely sensitive and therefore ideal for the 
intended purpose. The emergence in the last few years evidence o f the importance of 
VEGF to the behaviour of breast tumours makes the existence of a sensitive assay, 
usable on very small amounts o f tissue increasingly important.
The first part o f this work describes the production o f a riboprobe based on the 
published sequence o f VEGF RNA and attempts to use it for in situ hybridisation. 
Attempts to carry out immunohistochemisty using some antibodies which had recently 
been produced are also described. These techniques yielded little success.
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Discussions with workers in other laboratories confirmed that the available antibodies 
were not ideal for immunohistochemistry. Since these techniques are difficult to 
quantify and require larger samples o f tissue, the PCR based technique had greater 
potential for yielding an assay suitable for the intended purposes stated above, the 
focus o f the work moved to this assay. The development and optimisation of this 
assay and it use in a pilot study to determine the relationship between the amount of 
VEGF mRNA in archival tumours and the clinico-pathological behaviour of those 
tumours is described in the subsequent sections o f the work.
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Chapter 2. Cloning of VEGF Sequence into an 
Expression Vector
2.1 Introduction
The aim o f this part o f the work was to clone a section o f DNA derived from the 
VEGF cDNA sequence. A section was chosen from the first exon o f the VEGF gene, 
which is common to all splice variants. By splicing this sequence into an expression 
vector, it could then be used as a template to produce RNA molecules with a 
sequence complimentary to the VEGF RNA. These could be used as a probe to 
detect VEGF RNA by hybridisation.
2.2 Methods
2.2.1 Reverse Transcription Reaction.
RNA that had been purified from phorbol-activated HL60 cells was used. This was 
diluted in DEPC treated water and the optical density o f the solution determined at 
260nm on a Beckman DU-600 spectrometer. The RNA solution was then further 
diluted to a final concentration of lpg/pl.
Reverse transcription was carried out using the Perkins Elmer RT-PCR kit. One 
microgram of HL60 RNA was mixed with PCR reaction buffer, 4pl of 25mM MgCl2  
20 units of RNAase inhibitor, 8pi o f 2.5mM dNTPs, either lOOng o f VEGF 3' 
oligonucleotide or 5nmol random hexomers and 50u o f MuLu reverse transcriptase in 
a final volume o f 20pl. A negative control was set up as above with random 
hexomers but no reverse transcriptase.
The reaction mixes were incubated at room temperature for ten minutes then at 42°C 
for forty five minutes. They were then denatured at 99°C for five minutes and cooled 
on ice.
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2.2.2 Polymerase Chain Reaction.
Primers which amplify a 330 base pair segment of cDNA complementary to part of 
the first exon o f VEGF mRNA, common to all five splice variants, were designed with 
the help o f Dr Richard Lamb, Beatson Institute, Glasgow and were synthesised by 
Cruachem, Glasgow. They include a terminal Eco R1 endonuclease restriction site to 
facilitate plasmid ligation.
Primers were as follows:
5’ CGG GAA TTC CCT TGC TGC TCT ACC TCC ACC AT 
3’ CCG GAA TCC GAA GCT CAT CTC TCC TAT GTG CT
The polymerase chain reaction was carried out using the Perkins Elmer RT-PCR kit. 
A further 4fil o f 25mM MgCl2 together with PCR buffer and water to a volume of 
77pl was added to the products o f each of the four reverse transcription reaction. 
lOOng o f VEGF or CD44 3' and 5’oligo was added to the random hexomer VEGF 
and positive control reactions respectively and to the -RT negative control. Two and a 
half units o f Taq polymerase were then added to each reaction mix in a final volume 
of 80pl. The reaction mix was overlaid with 20pl o f mineral oil to prevent 
evaporation
The mixtures were denatured at 95°C for five minutes, annealed at 55°C for five 
minutes and extended at 73°C for fifteen minutes. They were then subjected to 30 
cycles of denaturation at 95°C for one minute, annealing at 55°C for one minute and 
extension at 73°C for five minutes.
2.2.3 Gel Electrophoresis
One hundred millilitres o f 1.2% solution o f agarose in Tris-borate buffer (TBE) 
(0.045M Tris-borate, 0.001M EDTA) was prepared and heated in a microwave oven 
to dissolve the agarose. The solution was allowed to cool to 60°C. One microlitre of
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ethidium bromide at lOmg/ml was added and the solution poured into an 8x1 Ocm gel 
mould. The gel was allowed to set for forty five minutes then placed in a tank 
containing TBE buffer with ethidium bromide added.
Ten microlitres from each PCR reaction was mixed with 2pl o f loading buffer (0.25% 
bromophenol blue, 0.25% xylene cyanol FF, 30% glycerol in water) and loaded on the 
gel beside molecular weight markers. The gel was run at lOOv for two hours.
2.2.4 Five Prime End Labelling of Oligo Probe.
A further oligonucleotide was created complementary to an area in the centre of the 
sequence that should be generated by the PCR reaction above. This was synthesised 
by Cruachem, Glasgow.
It had the following sequence:
GGCTGCT GC AAT GACGAGGGCCT G
It was used to produce a probe to confirm the identity o f the PCR product prior to 
cloning. End labelling o f this oligonucleotide with y^P dATP was carried out using 
the enzyme T4 Polynucleotide Kinase (PNK). A 20pl reaction was set up containing 
200ng o f the internal oligonucleotide, 2pi o f lOx PNK buffer, 2pl of lOOmM DTT, 
3 pi o f [y32?] dATP with an activity o f lOpCi/pl and lpl of T4PNK. This mixture was 
incubated at 37°C for one hour. The reaction was then stopped and the DNA 
precipitated by addition o f lp l o f 0.25M EDTA, lpl of lOpg/pl glycogen, lOpl of 
7.5M ammonium acetate and lOOpl o f ethanol. This mixture was stored at -70°C for 
fifteen minutes and centrifuged at 14,000rpm for fifteen minutes at 4°C. The resulting 
pellet was washed with 70% alcohol and re-suspended in lOOpl o f water. The activity 
o f the resulting labelled probe was determined by scintillation counting.
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2.2.5 Southern Blotting and Hybridisation.
The gel was blotted overnight onto a Hybond N+ filter using 0.4M NaOH. The filter 
was then washed with 2x SSC.
Prehybridisation buffer was prepared. This was composed o f 6x SSC salt solution 
(sodium chloride / sodium citrate), lOx Denhard’s reagent (Ficoll, Polyvinyl 
pyrollidone and bovine serum albumin), 0.5% sodium dodecyl sulphate (SDS) and 
denatured salmon sperm DNA (50pg/ml). The membrane was sealed in a plastic bag 
with pre-hybridisation buffer and incubated for one hour in a 65°C shaking water bath. 
The radio-labelled oligonucleotide probe was then added to the buffer and incubated 
overnight in a 65°C shaking water bath.
The filter was then washed in 6x SSC, 0.1% SDS for fifteen minutes at room 
temperature then at 65°C for one hour. The periphery o f the filter was checked with a 
Geiger counter to ensure that the washing was adequate (<10cpm). The membrane 
was resealed in a bag and placed in a radiographic cassette with X ray film overnight 
at -70°C. The film was then processed using an automated x-ray film processor.
2.2.6 ECO R1 Digests
The PCR product was purified by extracting twice with phenol and once with 
chloroform. It was then precipitated with sodium acetate and alcohol at -70°C and 
washed with 70% alcohol. The product was re-suspended in 30pl o f water. Prior to 
ligation o f the product into a plasmid vector, the cloning sites on the plasmid and 
insert must be exposed by endonuclease digestion.
An ECO R1 digest was set up with 30pi o f the PCR product, React 3 buffer, 25nMol 
spermidine and 20 units o f EcoRl in 50pl o f water. A further digest was set up with 
lpg  o f bluescript SK plasmid in the same way. Both mixtures were incubated at 37°C 
overnight. Ten microlitres o f each digest were then mixed with 2pi o f loading buffer 
and run on a TBE-agarose gel containing ethidium bromide as previously described.
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2.2.7 Plasmid Ligation.
Using the gel to estimate the relative concentration o f PCR product, a ligation mix 
was set up containing an approximately three-fold excess o f insert (PCR product) 
over plasmid. In order to prevent ligation without an insert, phosphatase-treated 
bluescript was used. Plasmid and insert were combined in a solution o f ligation 
buffer, 50mMol rapt and 2U of T4 DNA ligase in a total volume o f 50pl.
Three control ligation mixes were set up. The first contained bluescript that had been 
ECO R1 digested but not phosphatase-treated. No insert was added. This was 
intended to test the efficiency o f the ligase enzyme. The second control contained 
phosphatase-treated bluescript but no insert to test the extent o f self-ligation of the 
plasmid. The third contained phosphatase-treated plasmid and a commercial test 
insert with ECO R1 ends with a known high ligation rate. The mixtures were 
incubated at 12°C for eighteen hours.
2.2.8 Preparation of Competent E. Coil.
An overnight culture o f XL-1 E. coli was prepared. One millilitre o f this culture was 
added to 100 ml o f L-Broth. This was then incubated at 37°C in a shaking incubator. 
The bacteria were pelleted by centrifugation at 560g for ten minutes. The bacteria 
were then re-suspended in 20ml o f lOmM M gS04 (10ml in each o f two 50ml Falcon 
tubes) and kept on ice for five minutes. This solution was then centrifuged as before. 
The supernatant was discarded and the bacteria re-suspended in 20ml o f 50mM CaCl2 
(10ml per tube). This mixture was kept on ice for thirty minutes then centrifuged as 
before. The pellets from each tube were re-suspended in lml o f 50mM CaCl2 and 
combined.
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2.2.9 Transformation of E. coli
Falcon tubes (Type2059) were cooled on ice. One hundred microlitres of either XL-1 
bacteria rendered competent by the above method or DH5a competent bacteria were 
placed in each tube. Five microlitres o f each ligation mix was added to each tube. 
Two further controls were also set up, one with intact, unligated bluescript plasmid 
added to the bacteria and one with bacteria alone. The mixtures were kept on ice for 
one hour. They were then heat shocked for forty five seconds (DH5a) or two 
minutes (XL-1) and placed back on ice. Nine hundred microlitres of L-broth was 
added to each tube and they were incubated at 37°C in a shaking incubator for one 
hour.
Nine hundred microlitres o f L-Broth bacterial culture medium was added to each 
tube. The tubes were placed in a shaking incubator at 37°C for one hour.
The bluescript plasmid cloning vector confers ampicillin resistance on host bacteria. 
Therefore transfected bacteria can be selected for using ampicillin-containing media. 
The cloning site of the bluescript plasmid lies within the P-galactosidase gene. 
Therefore successful ligation of a DNA segment into this plasmid will inactivate this 
enzyme. If transformed bacteria are cultured in the presence of the lac operon inducer 
homologue, IPTG, and the chromogenic substrate, x-gal, cells transfected with 
plasmids which have not undergone ligation at the multiple cloning site will produce a 
blue colour change.
One and a half grams of bacterial grade agar (Bactagar) was mixed with 100ml of L- 
Broth and autoclaved. Ampicillin was added to a concentration o f 50|xg/ml along 
with IPTG and x-gal. Agar plates were poured and allowed to set. lOOpl o f each of 
the liquid cultures described above was smeared onto separate agar plates. Plates 
were then cultured overnight at 37°C. The blue and white colonies on each plate were 
counted and the white colonies harvested for characterisation.
41
2.2.10 Preparation of Master Clone Plates
Agar plates containing L-Broth, ampicillin, X-Gal and IPTG were prepared as above. 
The plates were laid on a colony identification grid and an orientation mark made. 
Bacterial clones were transferred to the master plate by picking up some of the 
original colony with the tip o f an autoclaved wooden toothpick. This was stabbed 
several times into the agar plate overlying a single numbered square on the grid and 
then the square o f the same number on a replicate plate. Two non-recombinant blue 
colonies were transferred onto each plate in this way to act as controls and the 
remainder o f the grid squares inoculated with white colonies. A total o f 100 colonies 
were transferred onto these plates.
2.2.11 Identification of Recombinant Clones by PCR
Colonies were screened for inserts using a technique described by Kilger and Schmid 
[120]. Part o f each white colony believed to contain an insert was picked up with a 
sterile toothpick. The bacteria were then smeared into a PCR tube and the toothpick 
used to inoculate a new agar plate, which was placed on a colony grid so that its 
position could be identified. The PCR tubes were microwaved for two minutes at 
600W to rupture the bacteria. PCR master mix containing the 3’ and 5’ PCR primers 
described above was added to each tube and the PCR reaction carried out as before. 
Products were electrophoresed on an agarose gel and the presence o f product 
confirmed by ethidium bromide fluorescence. For further confirmation o f the identity 
o f the product, Southern blotting and hybridisation with the radio-labelled internal 
oligonucleotide was carried out as before.
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2.2.12 Mini Plasmid Preparation.
Smears were taken with a cocktail stick from eighteen colonies that did not show any 
blue colouration on the master plates. Each stick was placed in 5ml of L Broth 
containing 50p.g/ml Ampicillin and incubated overnight.
One and a half millilitres o f each culture was spun in a microcentrifuge tube for fifteen 
seconds to pellet the bacteria. The pellet was then re-suspended in lOOpl of a 
solution o f 50mM glucose, 25mM Tris pH8 and lOmM EDTA pH7.5. 200pl of 0.2M 
NaOH + 1% SDS was added. The tubes were gently mixed and placed on ice for five 
minutes. One hundred and fifty microlitres o f cold 5M potassium acetate was then 
added to each tube and they were placed on ice for a further five minutes to 
precipitate the bacterial protein. This protein was then pelleted by spinning the tubes 
for one minute at 14 000 rpm in an Ependorph microcentrifuge. The supernatant 
formed was mixed with an equal volume o f 1:1 phenol/chloroform, centrifuged for 
five minutes at 14 000 rpm and then the top layer preserved. Boiled RNAase was 
added to a final concentration o f 10pg/ml and incubated for thirty minutes at room 
temperature. A quantity o f 7.5M ammonium acetate solution equal to half the 
residual volume was added and the tubes placed on ice for twenty minutes before 
being centrifuged at 14000 rpm for two minutes. The supernatant was then mixed 
with twice its volume of ethanol and precipitated at room temperature for ten 
minutes. The precipitate was pelleted by centrifugation for five minutes. The pellet 
was washed with 70% ethanol, dried in a lyophyliser and re-suspended in 50pl of TE 
buffer.
Fifteen microlitres o f each sample were then digested overnight with ECO R1 as 
before. Ten microlitres of each digest were then run on a 1% agarose-TBE gel, 
blotted onto Hybond N+ membrane and hybridised with 5' end labelled VEGF internal 
oligonucleotide as described above.
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2.2.13 Further Digest of Restriction Sites within the Bluescript 
Multiple Cloning Site
The remaining 3 5 pi o f each mini-plasmid preparation was mixed with 4.5 pi o f react 4 
buffer, 2 pi o f lOOmmol spermidine, 12 U o f KPN I endonuclease and 8 U o f SMAI 
endonuclease. These mixtures were incubated overnight at 37°C. The solutions were 
then frozen on dry ice and lyophilised. The solute was re-suspended in lOpl of water, 
run on a 1% agarose-TBE gel, blotted onto Hybond N+ membrane and hybridised 
with 5' end labelled VEGF internal oligonucleotide as before.
2.2.14 Large scale plasmid preparation
Five hundred millilitre cultures o f recombinant DH5a bacteria were grown by 
inoculating either L-Broth or terrific broth with 1ml of small-scale liquid culture in the 
presence o f ampicillin (50pg/l) and incubating overnight in a 37°C shaking incubator. 
The bacteria were sedimented by centrifugation at 5000 rpm (4°C) for ten minutes. 
The medium was drained and the bacteria re-suspended in 25 ml o f ice-cold buffer 
containing 50mM glucose, 25mM Tris (pH8), lOmM EDTA and 5mg/ml lysosyme. 
40ml of alkaline SDS (0.2M NaOH + 1% SDS) was added and the mixture kept on 
ice for five minutes. Twenty millilitres o f potassium acetate solution (2.5M potassium 
acetate, 5M acetic acid (pH=4.8)) were then added and the mixture kept on ice for 
fifteen minutes. The flocculate formed was sedimented by centrifugation at 8,000 rpm 
for five minutes. The supernatant was strained through gauze and a volume of 
isopropanol equal to 0.6x the collected volume added. This was left at room 
temperature for five minutes to precipitate nucleic acids and then centrifuged at 8,000 
rpm for five minutes. The supernatant was drained and the pellet re-suspended in TE 
buffer (pH8) (5ml o f TE per 500ml o f culture). Caesium chloride (1.5g/ml) and 
Ethidium Bromide (0.1 ml of lOmg/ml solution per ml o f TE) were added and the 
refractive index adjusted to 1.395. After two unsuccessful attempts at density gradient 
separation a further centrifugation at 10,000 rpm for ten minutes was added to 
remove the precipitate formed after addition o f ethidium bromide. The mixture was
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then transferred to ultracentrifuge tubes and centrifuged for forty hours at 40 000 rpm 
in an ultracentrifuge (Beckman).
Under UV illumination the lowest o f the fluorescent bands in the tube was aspirated. 
The ethidium bromide was removed by five extractions with isopropanol, the volume 
of the aqueous phase being restored between each extraction with TE buffer.
Caesium chloride was removed by placing the solution in collodium tubes and 
dialysing against TE buffer in a stirred bath at 4°C for twenty four hours with regular 
changes o f buffer. The optical density at 260nm and 280nm was measured on a 
spectrophotometer.
2.2.15 Sequencing of Product
Sequencing gels were first prepared. Two glass plates were washed with soap then 
alcohol. One plate was siliconised on one side with Sigmacote. The plates were then 
assembled with 0.4 mm spacers between. The plates were then taped and clamped 
together.
Eight percent polyacrilamide sequencing gel was prepared. This contained 21g of 
urea, 21ml o f water, 5ml o f lOx TBE buffer, 10ml o f 40% acrilamide/2% bis solution 
and 250|ig o f ammonium persulphate. Immediately before pouring, 24jil o f TEMED 
was added to commence polymerisation. The gel was then poured and a comb 
inserted to create wells.
Four micrograms of the DNA prepared in the large-scale plasmid preparation was 
used. This was denatured by addition o f 2pl 2M NaOH/ 2mM EDTA and incubation 
at 37°C for twenty minutes. Three microlitres o f ammonium acetate (pH4.5) were 
then added followed by lOOpl o f ethanol and the mixture placed at -20°C overnight to 
precipitate. The DNA was pelleted by spinning for fifteen minute spin in a 
refrigerated microcentrifuge and the pellet washed with 70% alcohol.
45
Sequencing was carried out using the Sequenase version 2.0 DNA sequencing kit. 
(United States Biochemical). The DNA pellet was re-suspended in 7(il o f water. 
Two microlitres o f sequencing buffer and lpl o f sequencing primer were then added. 
The mixture was heated to 65°C for two minutes and allowed to cool slowly over 
thirty minutes to allow primer annealing. It was then placed on ice. Labelling 
reactions were then set up by adding lpl o f 0.1M dithiothreitol (DTT), 2pi of 
labelling mix (diluted 1:5), 0.5pl o f [35S]dATP and 2pl o f Sequenase DNA 
polymerase (diluted 1:8 by mixing 1ml with 0.5pl of pyrophosphatase and 6.5 pi of 
enzyme dilution buffer). Four termination tubes were set up which contained all four 
deoxynucleotides and in different tubes one nucleotide as the dideoxynucleotide 
(ddNTP) analogue. This terminates the polymerase reaction at the incorporation sites 
of that ddNTP creating a range o f different length products all terminating at the same 
base in each tube. After running the labelling reaction for three minutes at room 
temperature to allow incorporation o f the radio-labelled dATP into the DNA chains, 
3.5ml of labelling mix was mixed with 2.5ml o f each o f the four termination mixtures. 
These tubes were incubated at 37°C for five minutes before the addition o f 4pl of 
sequenase stop solution (95% formamide, 20mM EDTA, 0.05% Bromophenol blue, 
0.05% Xylene cyanol FF) to each.
These reactions were then repeated using the reverse primer that creates chains o f the 
opposite sense reading from the other side o f the multiple cloning sites.
The sequencing gel was placed in a gel tank with IX TBE in the buffer chambers. A 
power supply was connected giving a constant power o f 55 watts at 2000 volts. 
After pre running for thirty minutes, the samples were loaded onto the gel and run 
until the dye front approached the bottom of the gel.
The siliconised plate was then removed leaving the gel adhering to the other glass 
plate. The gel was then washed in 10% acetic acid for ten minutes. The gel was then 
removed from the glass plate onto a sheet o f blotting paper, covered with cling film 
and dried in a vacuum gel dryer. It was then placed in an x-ray cassette overnight
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| with a sheet o f fast and slow X ray film. These films were developed in an automatic
processor. The sequence of the insert was read from the plates.
2.2.16 Preservation of Cloned Lines
Lines were preserved in two ways. Stab cultures were made by impregnating the 
bacteria into vials o f L Agar with a needle. Glycerol stocks were prepared by freezing 
the bacteria to -70°C in glycerol.
2.3 Results
2.3.1 RT-PCR
Gel electrophoresis of the RT-PCR products showed a band with the sample in which 
3' oligonucleotide had been used in the reverse transcription reaction. Blotting and 
hybridisation with 32P end labelled oligonucleotide complementary to the expected 
sequence o f the central region o f the PCR product produced a strong signal in the 
position o f the band thought to represent the VEGF PCR product.
2.3.2 Plasmid Ligation and Bacterial Transformation
An ECO R1 digest o f the PCR product was carried out to produce single stranded 
ends. Bluescript plasmid was digested as a control. Gel electrophoresis of the 
digested PCR product, the bluescript control and a sample of pre-digested 
phosphorolased bluescript was carried out. This revealed a bands of corresponding to 
the expected molecular weights. Ligation o f the PCR product into pre- 
phosphorolased bluescript plasmid and transformation o f competent XL-1 E. coli was 
carried out as described.
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Whilst a low incidence o f recombinant colonies was seen with the test insert, none 
were seen with the PCR product.
It appeared that the ligation efficiency was lower with the PCR product than with test 
insert. Possible explanations were that the ECO R1 sites on the ends o f the PCR 
product had not been fully digested by the enzyme or that the small oligonucleotides 
formed from a successful digestion o f these ends were subsequently attaching to the 
ECO R1 sites on the open ends o f the plasmid thus blocking ligation o f the PCR 
product. Measures were therefore taken to overcome these two potential problems.
To improve digestion efficiency, the PCR product was subjected to a proteinase K 
treatment prior to ECO R1 digestion. The ECO R1 digest was then run on a 1.4% 
agarose gel. A single band corresponding to the expected weight o f the PCR product 
was seen. This was cut out in a block, dissolved and phenol chloroform extracted. 
Ligation and transformation were carried out as before. A stock o f pre-competent 
DH5a bacteria was available and these were used. Results are shown below.
Plate Number Description White Colonies Blue Colonies
1 Unphosphorolased
Plasmid
0 >1000
2 No insert 2 83
3 Test Insert 280 20
4 PCR product 180 150
5 Undigested Plasmid 0 >1000
6 Untransformed
Bacteria
0 0
Table 1. Bacterial transformation with cloned plasmid
180 colonies o f bacteria which appear to have been transformed by cloned plasmid 
were produced
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2.3.3 Characterisation of Clones
Colonies from plate 4 which appeared white were transferred to master plates and 
cultured overnight. Some of the colonies showed a blue colour after this further 
growth but eighteen colonies that did not and were therefore believed to be 
recombinant were selected.
Products o f PCR of microwaved smears were run on agarose gels. Bands of the 
expected size were seen from ten clones. When the gel was blotted onto nylon 
membrane all o f these and a further four which did not yield a visible band on the gel, 
hybridised with 32p labelled internal oligonucleotide.
The small-scale plasmid preparations were subjected to ECO R1 digestion. The gel 
was blotted on to nylon membrane and subsequent hybridisation with 32p labelled 
internal oligonucleotide confirmed the presence o f the VEGF insert in fourteen out of 
the eighteen clones. One of the colonies was selected for large-scale plasmid 
preparation as describe above.
2.3.4 Sequencing
A sample o f the product o f the large scale plasmid preparation was subjected to DNA 
sequencing. Sequenase sequencing reactions were carried out as described. The gel 
obtained is illustrated in figure 1. The base sequence o f the insert and adjacent 
plasmid were derived from the gel and compared with the predicted sequence as 
shown in the appendix. The sequence was as expected.
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Figure 1 The sequencing gel
2.5 Discussion.
It has proved possible to generate cDNA corresponding to part of the published 
sequence o f the first exon o f VEGF. This part o f the molecule is common to all splice 
variants. The identity o f this cDNA was confirmed by verification o f its size using gel 
electrophoresis, by hybridisation with a DNA probe based on part o f its expected 
sequence and ultimately by chain-termination DNA sequencing. This piece of cDNA 
was cloned into an insertion vector to allow synthesis o f RNA probes for use in 
further work.
In the course o f this work it was found that this part o f the VEGF sequence could 
reliably be amplified by PCR even from plasmid DNA within crude bacterial lysates. 
The success o f these PCR primers formed the basis o f the development o f the semi- 
quantitative PCR assay o f VEGF described later.
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Chapter 3. Preparation and Testing of Riboprobes
3.1 Introduction
Various probes can be used for hybridisation with RNA. Whilst short 
oligonucleotide DNA sequences can be readily synthesised and make convenient 
probes, larger riboprobes produced from RNA transcripts have the advantage o f a 
longer length o f binding. . RNA-RNA binding has higher affinity compared to RNA- 
DNA binding. The preceding chapter describes how part o f the VEGF sequence was 
cloned into the bluescript plasmid expression vector. This allows the production of 
RNA sequences complementary to cellular mRNA
To allow detection o f the hybridised probe, it must carry a detectable label. Initially 
hybridisation techniques relied on radioactive labels that could be detected by 
autoradiography. This method carries with it the problems o f the risks o f handling of 
radioactive material, the limited shelf life of probes and the time required for 
autoradiography. More recently, non-radioactive methods such as the biotin labelling 
or digoxigenin system (Boeringer Mannheim) have been developed. These overcome 
the problems associated with radioactive methods and can yield higher resolution by 
avoiding scatter o f radiation during autoradiography. This system was used in this 
work.
The aim of this part of the work was to create a VEGF riboprobe based on the cloned 
sequence by in vitro transcription and to test its ability to hybridise to mRNA.
3.2 Methods
3.2.1 Preparation of linearised plasmid templates.
Linearised plasmid construct templates for the preparation o f sense and antisense 
riboprobes were made. This was done by cutting the construct with restriction 
endonucleases on the side o f the insert opposite the enzyme promoter. To make a
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template for the antisense probe for use with T7 transcriptase the construct was 
digested with PST I endonuclease. The template for the sense probe for use with T3 
transcriptase was created using ECO RV endonuclease.
Digests were set up containing 40.5(il of the dialysed plasmid solution previously 
prepared, 5(0,1 o f lOx enzyme buffer as appropriate for the enzyme (React 2 buffer, 
Gibco BRL for PST I and Reaction buffer 4, NBL for ECO RV). Two and a half 
microlitres o f lOmmol spermidine was added followed by 2|ol o f the appropriate 
enzyme (PST I, 8u/(il, Gibco BRL or ECO RV 12u/pl, NBL). This gave a 
concentration o f plasmid construct o f about 0.1 l|o,g/(ol in the reaction mix. Control 
reactions for each enzyme were set up using an equivalent amount o f bluescript 
plasmid. The mixtures were incubated overnight at 37°C. Fifty microlitres o f DEPC 
treated water was then added to each mixture. They were purified by a 
phenol/chloroform extraction followed by a chloroform extraction as has been 
previously described. The resulting aqueous phase was precipitated by adding IOjliI of 
sodium acetate and 200|il o f ethanol and storing at -20°C overnight. The resulting 
pellet was washed with 70% ethanol then re-suspended in 10|al o f DEPC treated 
water. Two microlitres o f each solution, including the bluescript controls, were 
electrophoresed on a 1.2% agarose gel to ensure purity and completeness o f the 
digestion.
3.2.2 Transcription of digoxigenin-labelled riboprobes.
Transcription reactions were set up containing l(ig o f linearised plasmid template, 2(il 
of digoxigenin labelling mixture (lOmM ATP, lOmM CTP, lOmM GTP, 6.5 mM 
UTP, 3.5mM DIG-11-UTP in Tris-HCl pH 7.5, Boeringer Mannheim), 2|nl of lOx 
transcription buffer (400mM Tris-HCl pH 8, 60mM MgCb, lOOmM DTT, lOOmM 
NaCl, 20mM spermidine, RNAase inhibitor lU/|il, Boeringer Mannheim), 40 units of 
T7 (for antisense) or T3 (for sense) RNA polymerase (Boeringer Mannheim) made up 
to a total volume o f 20\i\ with DEPC treated water. On the first occasion that the 
transcription was carried out, an enzyme-free control reaction was also included. The 
mixture was incubated in a 37°C water bath for two hours. The reaction was then
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stopped by the addition of 2p,l o f 200mM EDTA pH 8. The RNA was then 
precipitated by the addition of 2pl o f 4M LiCl and 60pl o f cold ethanol. This mixture 
was incubated at -70°C for half an hour then centrifuged at 14 000 rpm for fifteen 
minutes in an Ependorph microcentrifuge. The pellet was washed with lOOfil o f 70% 
ethanol in DEPC treated water and again centrifuged at 14 000 rpm for five minutes. 
The alcohol was removed and the pellet lyophilised in a freeze dryer before being re­
suspended in lOOpl o f DEPC treated water.
Labelling o f the probe was checked with dot blots on Hybond N+ membranes. After 
the first transcription duplicate lpl samples o f the T3, T7 and enzyme-free controls 
were dotted onto Hybond N+ membrane and allowed to air dry for one hour before 
being cross-linked by exposure to ultra violet for five minutes. For subsequent 
transcriptions, the amount o f labelled probe was compared with previous reactions by 
preparing serial dilutions o f the new and old probes, which were then dotted onto the 
membrane and treated as above.
3.2.3 Detection of Probe
The membrane was washed for five minutes in detection buffer 1 (lOOmM maleic 
acid, 150 mM NaCl pH 7.5). It was then blocked by incubation for thirty minutes at 
room temperature in 1% blocking reagent for nucleic acid hybridisation (Boeringer 
Mannheim) in detection buffer 1 and incubated with anti-digoxigenin-AP Fab 
fragments (Boeringer Mannheim) diluted 1:5000 in 1% blocking reagent solution.
The membrane was then washed twice for fifteen minutes each time in buffer 1. It 
was equilibrated with detection buffer 3 (lOOmM Tris-HCl pH 9.5, lOOmM NaCl, 
50mM MgC12.) for two minutes. Forty five microlitres o f NBT solution (75mg/ml 
nitro-blue tetrazolium salt in 70% dimethylformamide, Boeringer Mannheim) and 
35jnl of BCIP solution (50 mg/ml 5-bromo-4-chloro-3-indolyl phosphate toluidinium 
salt in 100% dimethylformamide, Boeringer Mannheim) were diluted in 10ml of 
detection buffer 3. The membrane was incubated with this in a sealed nylon bag in the 
dark overnight. It was then washed in TE buffer (lOmM Tris, ImM EDTA pH 8).
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3.2.4 Isolation of RNA from cultured cells.
Extraction was carried out with TRIzol (Gibco), a mono-phasic solution of phenol 
and guanidine isothiocyanate. Cells were grown to confluence in a tissue culture 
flask. Culture medium was removed and the cells re-suspended in TRIzol, 1ml per 
10cm2 of flask). The cells were lysed by pipetting. Chloroform (0.2 ml o f per ml of  
TRIzol) was added. The tube was shaken for fifteen seconds and left at room 
temperature for three minutes before being centrifuged at 11 600g in a 
microcentrifuge at 4°C for fifteen minutes. The aqueous phase containing the RNA 
was removed leaving the DNA and protein in the organic phase.
To precipitate the RNA, 0.5 ml o f isopropyl alcohol per ml o f TRIzol used was added 
and left at room temperature for ten minutes. The RNA was pelleted by 
centrifugation at 11 600g at 4°C for ten minutes. The supernatant was removed. The 
pellet washed in 1ml o f 75% ethanol then centrifuged at 7250g at 4°C for five 
minutes. The ethanol was removed and the pellet dried in a freeze drier for 5 minutes. 
The pellet was re-suspended in 0.5% SDS solution in DEPC treated water and 
incubated for ten minutes at 55°C to ensure complete dissolution. The optical density 
of the solution was then measured at 260 and 280 nm.
3.2.5 Determination of optimal probe concentration for hybridisation.
Samples o f RNA were precipitated as described for gel electrophoresis and re­
suspended at a concentration o f lOfig /pi in RNA diluting buffer (5:3:2 mixture of 
DEPC-treated water, 20x SSC and formaldehyde).
Six 5mm x 5mm squares o f Hybond N+ membrane were cut. One microlitre of RNA 
solution was dotted onto three o f the squares, air-dried for one hour and cross-linked 
by exposure to ultra-violet light for five minutes.
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Hybridisation buffer as described in the Boeringer DIG system protocols was 
prepared containing 50% formamide, 5x SSC, 0.02% SDS, 0.1% N-lauroylsarcosine, 
2% blocking reagent for nucleic acid hybridisation (Boeringer Mannheim). All six 
squares were incubated for one hour in this solution at 68°C
Hybridisation solutions were prepared by adding the product o f the T7 transcription 
reaction the prehybridisation buffer in dilutions o f lul/ml, 3 pl/ml and 5 pl/ml. These 
solutions were placed in 1ml screw top tubes and placed in a boiling water bath for 
ten minutes to denature the probe. One piece o f membrane with RNA dotted on and 
one piece without RNA were then place in each hybridisation solution and incubated 
at 68°C overnight. The squares were then transferred to a small plastic box. They 
were washed twice at room temperature for five minutes with wash solution 
containing 2x SSC with 0.1% SDS and twice for twenty minutes at 68°C with wash 
solution containing O.lx SSC and 0.1% SDS. Detection was then carried out as 
described in section 3.2.3 above, except the incubations with antibody and colour 
substrate were carried out in 1 ml tubes.
3.2.6 Gel Electrophoresis of RNA samples.
The volume o f solution containing the required amount o f RNA (10-30pg) was 
calculated. The RNA was precipitated from this solution by the addition o f 0.1 vol of 
3M Na Acetate pH 5.4 and 2.5 vol o f absolute ethanol. The samples were then 
chilled for 5 minutes at -70°C before being centrifuged at 13530 g at 4°C for fifteen 
minutes. The supernatant was withdrawn and the pellet lyophilised. The pellet was 
then re-suspended in lOpl o f RNA loading buffer. Immediately prior to being loaded 
onto the gel, the samples were denatured by heating to 65°C for fifteen minutes. One 
microlitre o f lpg/ml ethidium bromide was then added to each sample. Molecular 
weight markers were also prepared as above.
The electrophoresis tank, gel tray and comb were washed with detergent then soaked 
in 3% hydrogen peroxide for ten minutes. They were then washed with DEPC- 
treated water and air-dried.
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Gels were prepared containing 1.2 g agarose and 20ml lOx MOPS in DEPC-treated 
water per 100ml. The mixture was heated in a microwave oven until the agarose was 
fully dissolved 10ml formaldehyde per 100ml was added to the molten gel. The gel 
was then poured into a gel tray with a gel comb in place and it was allowed to set for 
thirty minutes before use.
The gel was then placed in an electrophoresis tank containing lx  MOPS buffer and 
the gel comb was removed. Samples and markers were loaded into the wells. 
Electrophoresis was carried out at 70v.
The gel was inspected and photographed under ultra-violet light.
3.2.7 Gel Electrophoresis of Probe.
An RNA electrophoresis gel was prepared as before. A 20pl sample o f the T7 RNA 
transcript was precipitated, lyophilised, re-suspended and denatured in the same way 
as the previous RNA samples used for Northern blotting. RNA molecular weight 
markers were also prepared in the same way.
3.2.8 Northern Blotting.
Blotting apparatus was set up as has previously been described for Southern blotting. 
The marker lane was excised and the gel trimmed. The RNA was blotted onto 
Hybond N+ membrane overnight using 20x SSC transfer buffer. The membranes 
were washed twice in 2x SSC for five minutes to remove adherent agarose then air- 
dried for two hours. The RNA was then cross-linked to the membrane by exposure to 
UV light for five minutes.
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3.2.9 Blotting and Detection of Probe
The RNA gel on which the T7 transcript had been electrophoresed was Northern 
blotted onto Hybond N+ membrane. This membrane was then subjected to the 
detection method described above to reveal the probe
3.2.10 Probing of membranes.
Nylon membranes, which had been blotted and cross-linked as above, were placed in 
hybridisation bags with 20ml/100cm2 o f Northern hybridisation buffer as described 
above and incubated for one hour at 68°C in a shaking water bath.
DIG labelled riboprobe prepared by T7 transcription from the VEGF plasmid 
construct was diluted in hybridisation buffer and denatured by placing in a boiling 
water bath for ten minutes.
The bag containing the membrane was drained and the probe hybridisation solution 
(probe in hybridisation buffer) was added. This was then incubated overnight at 68°C. 
The membrane was then washed twice at room temperature for five minutes with 
wash solution containing 2x SSC with 0.1% SDS and twice for twenty minutes at 
68°C with wash solution containing O.lx SSC and 0.1% SDS. Detection was then 
carried out as described under Detection o f Probe above.
3.2.11 Hybridisation Tests with Dot Blots
RNA from MCF7 cells, human heart and human liver were dot blotted onto two 
pieces o f Hybond N+ membrane as before. Hybridisation buffer previously used for 
Southern blotting in earlier work was used. This contained 50% formamide and 
salmon sperm DNA.
An antisense oligonucleotide probe was prepared by end labelling the 3’ 
oligonucleotide with digoxigenin.
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Since smaller oligonucleotide probes tend to have lower binding affinity, hybridisation 
and washes with this probe were carried out at lower temperatures to reduce 
stringency.
The membranes were prehybridised by soaking in hybridisation buffer at 68°C. 
Hybridisation solutions containing either 1:400 riboprobe or 1:20 oligonucleotide 
probe were set up. One membrane was soaked overnight in the riboprobe at 68°C and 
the other in oligonucleotide probe at 42°C. The membrane was then washed twice at 
room temperature for five minutes with wash solution containing 2x SSC with 0.1% 
SDS. The membrane hybridised with riboprobe was washed twice for twenty minutes 
at 68°C with wash solution containing O.lx SSC and 0.1% SDS. The membrane 
hybridised with the oligonucleotide probe was washed in the same solution at 42°C. 
Detection with alkaline phosphatase-conjugated anti-digoxigenin and substrate was 
carried out as before.
3.3 Results.
3.3.1 Preparation of Digoxigenin-Labelled Riboprobes.
Transcription reactions were set up as described with T3 & T7 transcriptase and a 
transcriptase-free control. Appropriate DNA templates were used for each enzyme. 
The probe produced in each transcription reaction was re-suspended in lOOpl of 
water and dot-blotted onto an N+ membrane in duplicate.
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Figure 2. Blot of Probe
It can be seen that both transcriptions give strong dot blots with the T7 being 
strongest. Only weak staining is seen with the transcriptase-free controls, which 
presumably resulted from adherence o f unincorporated DIG-UTP to the membrane.
3.3.2 Gel Electrophoresis and Blot of Riboprobe
Electrophoresis and blotting o f the probe revealed a dense band with a tail o f smaller 
residues representing incomplete or degenerate transcripts.
Figure 3. Blot of DIG labelled T7 transcript
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3.3.3 Estimation of Optimal Probe Concentration.
Small squares o f  Nylon membrane with or without MCF7 RNA dot-blotted onto them 
were subjected to hybridisation as described with probe dilutions o f 1,3 and 5 pi of 
probe per ml o f buffer.
No background staining o f  the membrane was seen at any o f these concentrations. 
Faint discolouration o f the membrane was seen in the central areas o f the squares 
which had been blotted with MCF7 RNA and exposed to the higher two probe 
concentrations.
3.3.4 Northern Blots.
RNA samples were electrophoresed and blotted onto Hybond N+ nylon membrane.
M CF7 RNA (30pg) 
Human Heart RNA (30pg) 
Human Liver RNA (30pg)
Figure 4. Photograph of RNA gel
Lane 1. 
Lane 2. 
Lane 3.
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After blotting and hybridisation, the membrane showed very high levels of 
background staining with no distinguishable bands.
3.3.5 Dot Blots
In order to determine whether the background staining was due to the problems with 
the blotting or hybridisation, dot blots were carried out.
Ten microgram dots o f MCF7 breast cell line derived RNA, human heart RNA and 
human liver RNA on Hybond N+ nylon membrane were hybridised with digoxigenin 
labelled riboprobe or oligonucleotide probe. The riboprobe again showed background 
staining o f the membrane. The oligo probe caused less background staining but no 
visible hybridisation to the RNA samples could be demonstrated.
3.4 Discussion
Digoxigenin labelled RNA transcripts were successfully obtained from the plasmid 
construct containing the VEGF insert. It was demonstrated that this transcript could 
be detected when bonded to nylon membranes. Attempts to use the probe for 
Northern blotting were hampered by non-specific binding to the membrane. 
Discussions with Boeringer suggested that his may be due to the level of charge on 
the Hybond N+ membrane and that Boeringer uncharged membrane may be more 
suitable. A sample o f this membrane was tested and did indeed result in lower levels 
of background. Since the PCR based assay described later appeared to offer greater 
sensitivity blotting with this paper was not pursued further. The probes were however 
used for in-situ hybridisation in an attempt to obtain information on the localisation of 
VEGF RNA expression within the tissue samples.
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Chapter 4 In Situ Hybridisation
4.1 Introduction
In situ hybridisation (ISH) techniques allow the detection o f nucleic acid in cells or 
tissue sections. It relies on the binding o f a nucleic acid probe to a complementary 
nucleic acid sequence within the cell. RNA hybridisation makes it possible to identify 
which cells are expressing a particular mRNA species and may therefore be producing 
a particular protein.
When used on archival fixed paraffin sections, the technique depends on the 
assumption that the fixation process has preserved the RNA species under study. 
These RNA molecules can then be made accessible by treatment with a protease such 
as proteinase K.
In order to distinguish specific hybridisation from non-specific binding o f probe, it is 
important to include controls with a probe o f similar characteristics to the test probe 
that is not expected to bind. A sense RNA transcript from the same construct used to 
generate the antisense probe makes a convenient control.
Whilst immunohistochemical methods will label cells which bind or take up a 
particular protein, RNA in situ hybridisation will only label cells producing the mRNA 
coding for that protein. However, the finding o f mRNA species within a cell does not 
necessarily mean that that this is undergoing translation to protein. ISH and 
immunohistochemistry therefore yield complementary information.
4.2 Methods.
4.2.1 Tissues
Formalin fixed, paraffin embedded sections of normal human kidney, normal human 
breast and ductal carcinoma of breast were kindly supplied by the Department of
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Pathology, Western Infirmary Glasgow. Detection of VEGF mRNA in the glomeruli 
of human kidneys has been reported [62] and it was therefore felt that this was a 
suitable test tissue for the technique
4.2.2 Preparation of Probes.
Riboprobe.
Preparation o f digoxigenin-labelled riboprobe from the cloned plasmid template 
containing part o f the VEGF cDNA sequence has been described in the preceding 
chapters.
Oligonucleotide probes
The antisense (3’) and internal sense oligonuclotides used previously in cloning the 
VEGF sequence into the plasmid were used as an oligonucleotide probe and sense 
control respectively. These were end-labelled with digoxigenin as previously 
described.
The labelled oligonucleotides were passed through a sepharose column and the 
fractions dot blotted onto nitrocellulose membrane. The fractions containing bound 
digoxigenin were lyophilised.
4.2.3 In -situ Hybridisation
After washing in xylene, sections were rehydrated along an alcohol / DEPC treated 
water gradient. They were then immersed in DEPC treated 0.2 N HC1 for twenty 
minutes then washed twice in DEPC treated PBS. The slides were then immersed in 
0.3% Triton X made up in 2x SSC at 70°C for fifteen minutes. They were then 
washed twice with DEPC treated PBS.
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Proteinase K dilutions were o f 0, 10, 20, 30, 40, 50 and 100 (xg/ml were prepared by 
diluting proteinase K in diluting buffer (0.1M Tris/HCl pH 8 + 50mM EDTA). Four 
slides were covered with each dilution of proteinase K and incubated at 37°C for 
thirty minutes. They were then immersed in 0.2% glycine in DEPC treated PBS for 
thirty seconds.
After being washed twice in DEPC treated PBS, the slides were post-fixed by 
immersion in 4% paraformaldehyde. They were again washed twice in DEPC treated 
PBS.
Prehybridisation buffer was by prepared diluting 30ml o f 20X SSC in 120ml o f water 
and adding 150ml o f formamide. The slides were immersed in this buffer for two 
hours at 37°C
Hybridisation buffer was prepared containing
40 j l x 1 of 5M Tris pH 7.5
2.5ml of Denhardt’s solution
1.3(0.1 o f 30X SSC
0.5ml of 20% SDS
10ml o f 100% formamide
4ml o f 50% dextran sulphate
0.5ml o f salmon sperm DNA (lOmg/ml)
1.16ml of Water
Antisense and sense (control) riboprobes and oligonucleotide probes were used at 
dilutions from 1:10 to 1:100 in this hybridisation buffer which had been preheated to 
either 37°C or 42°C. Twenty microlitres o f hybridisation buffer containing probe were 
placed on silicone coated cover slips and sections mounted onto these cover slips. 
They were then incubated in seated polythene bags with a moist paper towel 
overnight at either 37°C for oligonucleotide probes or 42°C for riboprobes.
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The coverslips were removed by rinsing the slides in 4X SSC. The slides were then 
washed twice in 2X SSC for twenty minutes each time at room temperature then 0. IX 
SSC for twenty minutes each time at 37°C for oligonucleotide probes or 42°C for 
riboprobes. They were then washed in 2X SSC for five minutes.
The digoxigenin conjugated to the probe was then detected with alkaline phosphatase 
conjugated anti-digoxigenin antibody. Detection buffer was prepared by adding 2.36g 
of Tris base and 12.7g o f Tris HC1 to 1 litre o f water and, after adjusting the pH to 7.5 
with HC1, adding 8.7g of NaCl. 20% human serum and anti digoxigenin antibody to a 
concentration o f 1:500 were added to detection buffer. The slides were then 
incubated with the antibody solution for two hours at room temperature. They were 
then washed twice for ten minutes in the plain detection buffer.
A further buffer was prepared by adding 12. lg  o f Tris base to a litre of water and 
adjusting the pH to 9.5 with HC1 before adding 5.8g o f NaCl and lOg o f MgCl2. The 
slides were washed for five minutes in this buffer. A Nitro-Blue Tetrazolium (NBT)/ 
Bromochloro-Indolylphosphate (BCIP) solution was prepared as a substrate for the 
conjugated alkaline phosphate enzyme. This was done by adding 198pl o f NBT stock 
solution (750mg o f NBT in 70% Dimethylformamide) and 150pl BCIP stock solution 
(500mg of BCIP in 10ml 100% Dimethylformamide) to 45ml o f this buffer and then 
adding 12mg of levamisole. The slides were immersed in this substrate solution 
overnight in a coplin jar wrapped in aluminium foil. The slides were then washed in 
distilled water. They were lightly counterstained with haematoxylin and washed three 
times in distilled water before being “blued” in Scott’s tap water substitute (STWS). 
They were washed again in distilled water before being mounted in glycergel.
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4.3 Results.
4.3.1 Preliminary Trial of Technique.
A trial of using the technique with an oligonucleotide probe (PMC) on rat pituitary, 
(which had previously produced staining), was attempted. The expected pattern of 
hybridisation was observed.
4.3.2 RNA Riboprobes.
Despite employing a range of proteinase K and riboprobe concentration the only 
staining that could be produced on human kidney sections was in the tubules. This 
was also seen when the sense control riboprobe was used and therefore appeared to 
be non-specific binding of probe.
Paraffin sections o f normal human breast and ductal carcinoma of the breast were also 
used. Again only non-specific staining was seen with both the antisense and sense 
riboprobe.
4.3.3 DNA Oligonucleotide Probes
Oligonucleotide hybridisation was attempted using the paraffin sections o f kidney. 
Both antisense and sense oligonucleotide probes stained the tubules. There was no 
difference in staining between the antisense test probe and the sense control probe, 
indicating that this binding was again non-specific.
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4.4 Discussion
No specific staining was seen with either probe on the tissue sections used. Whilst the 
identity o f the riboprobe template had been verified by DNA sequencing attempts at 
proving that it would hybridise to RNA extracts had proved unsuccessful. However 
given the failure o f both probes, the possibility exists that the VEGF RNA in the 
tissues under examination had been degraded. Trials on a more extensive range of 
tissue samples and the creation o f further probes would have been necessary to 
determine the cause o f the problem. However it had become clear from ongoing 
work on an RT- PCR based assay, described in chapter 6, that a quantitative assay 
would be required. It was therefore felt that the development o f this assay would be 
more fruitful and creation o f further probes was not pursued.
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Chapter 5 Immunohistochemistry
5.1 Introduction
Immunohistochemistry allows the identification and localisation o f proteins using 
antibodies linked to enzymes that produce colour changes in indicator dyes. The 
systems are frequently multi-step. This has the advantage both o f economy in 
allowing one enzyme-conjugated antibody to be used in the identification o f several 
different proteins and also o f building amplification into the system. Further 
amplification can be achieved by the use o f antibodies and enzymes that combine via 
binding proteins such as the avidin-biotin system.
Immunohistochemistry was one o f the first methods described for detection o f VEGF 
in tissues and some workers have reported success with this technique. Brown et al in 
Boston [62] demonstrated cytoplasmic staining for VEGF of visceral glomerular 
epithelial cells but not on the adjacent endothelium. They found that in renal cell 
carcinomas, there was staining of both the malignant cells and tumour vessels [63].
When this research was begun, VEGF staining by immunohistochemisty in breast 
tissues had not been reported. The ability to use immunohistochemistry in this way 
was felt to be a useful adjunct to the RNA detection methods described above. It has 
disadvantages in being difficult to quantify and in being affected by differences in the 
binding of VEGF protein to the tissue substrate. However it has the potential to 
confirm that VEGF mRNA was being translated into protein in the tissues.
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5.2 Methods
5.2.1 Tissues.
Formalin fixed, paraffin embedded sections o f normal human kidney, normal human 
breast & ductal carcinoma of breast and frozen sections o f human kidney were kindly 
supplied by the Department o f Pathology, Western Infirmary Glasgow.
5.2.2 Antibodies
Monoclonal anti-VEGF monoclonal antibody (A 4.6.1) [119] and rabbit polyclonal 
anti-VEGF antibody were gifts from Genentec Inc. San Francisco.
R&D monoclonal antibody (MAB293) against the 165 amino acid variant o f VEGF 
was purchased from R&D Systems (Abingdon).
Biotinylated goat anti-mouse antibody was used as second antibody for the 
monoclonal primary antibodies and biotinylated goat anti-rabbit antibody for the 
polyclonal antibody.
5.2.3 Preparation of Paraffin Sections
Sections were deparaffinised by two five minute soaks in Xylene then transferred 
100% ethanol. They were then rehydrated down an alcohol gradient by five minutes 
soaks in baths containing 95%, 80% and 50% ethanol. Sections were then transferred 
to TBS.
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5.2.4 Preparation of Frozen Sections
Sections were fixed by placing the slides in acetone for five minutes then TBS for five 
minutes.
5.2.5 Staining Procedure
Specimens were covered with 10% goat serum in TBS and incubated for sixty 
minutes at room temperature. Anti-VEGF antibody at titrated dilutions in TBS was 
applied to each tissue section. Control sections treated with only TBS were set up. 
Sections were incubated overnight at 4°C. They were then washed twice with TBS. 
A biotinylated species-specific second antibody against the primary antibody (diluted 
1/400 in TBS) was then applied to the sections and incubated for thirty minutes at 
room temperature. The slides were then washed twice with TBS. Alkaline 
phosphatase-conjugated streptavadin was then applied and incubated for thirty 
minutes. The slides were again washed with TBS. New fuchsin substrate was applied 
and incubated for thirty minutes. Slides were then counterstained in haematoxylin for 
forty seconds.
5.2.6 Antigen Unmasking Techniques
When the above protocol failed to yield any staining with paraffin sections, it was 
repeated with sections that had been subjected to antigen unmasking. Two 
techniques, enzymatic digestion and microwave antigen retrieval, were used both 
individually and in combination.
Enzymatic Digestion
Slides were place in pre-warmed (37°C) 0.1% trypsin in PBS for times ranging from 
five to sixty minutes. They were then washed in distilled water.
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Microwave antigen retrieval.
Citrate buffer pH 6.0 was prepared (3.8g o f citric acid, 2.4g o f sodium citrate per 
litre). Slides were immersed in this buffer in a coplin jar. They were then heated in a 
800W domestic microwave on 50% power for between five and twenty minutes. The 
buffer was then allowed to cool and the slides rinsed in distilled water.
5.3 Results.
5.3.1 Untreated Sections
No staining was seen on any o f the tissue section used with the three anti-VEGF 
antibodies.
5.3.2 Antigen Retrieval Techniques
Trypsin exposures in excess of thirty minutes produced significant tissue degradation. 
Microwave treatment followed by trypsinisation led to more tissue degradation than 
trypsinisation followed by microwave treatment.
No combination of trypsin o f microwave treatment yielded any staining with any of 
the antibodies or tissues.
5.4 Discussion
With the tissues and antibodies used, no immunostaining for VEGF was observed. 
This may be due to tissue preparations methods. The antigen unmasking techniques 
used would be expected to compensate for problems resulting from fixation. No 
staining was seen with the frozen sections o f cell lines. Discussions with other 
groups suggested that the available antibodies at that time were not ideally suited for 
immunohistochemistry. The majority o f workers have used an ELISA technique to 
measure VEGF protein. It appeared that with the antibodies available at the time of  
this study, immunohistochemistry was not a viable way o f assessing VEGF in breast 
tissues. Since completion of this work, two groups [91, 96] have however reported 
staining of breast carcinomas for VEGF with polyclonal and monoclonal antibodies.
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Chapter 6. Development and Optimisation of Assay 
for the measurement of VEGF mRNA by RT-PCR
6.1 Introduction.
6.1.1 The Polymerase Chain Reaction.
The polymerase chain reaction is a technique for reproducing segments o f DNA. It is 
able to reproduce very rapidly, large amounts o f a defined DNA segment from 
nanogram amounts o f template DNA, within a large background o f irrelevant 
sequences. This has led to it becoming one o f the most important techniques in 
molecular biology. Tiny traces of DNA can be amplified sufficiently to be visible on 
an electrophoretic gel allowing them to isolated and sequenced.
The technique relies on having unique, known sequences o f DNA flanking the 
segment to be amplified. It is not necessary to know the intervening DNA sequence. 
Short DNA oligonucleotides complementary to the flanking sequences are required. 
These are called primers. If DNA is heated sufficiently to denature the double helix 
into single stands then allowed to cool, double stranded DNA will re-form. If this is 
carried out in the presence o f a large excess o f oligonucleotide primers 
complementary to the sequences flanking the area o f interest, these primers will 
preferentially anneal to that area. Allowing this to happen in the presence of a DNA 
polymerase enzyme will result in that enzyme producing a second strand, 
complementary to the segment o f interest, starting from the primer. This process 
could then be repeated by re-heating the DNA to denature it again. This re-heating 
would denature most DNA polymerases and further enzyme would need to be added. 
However the DNA polymerase of the thermophile algae Thermus aquaticus (Taq.) is 
stable at temperatures sufficient to cause double stranded DNA to disassociate [103], 
This allows a rapidly repeating cycle o f denaturation, primer annealing and sequence 
extension to be carried out. This is called a polymerase chain reaction (PCR). Saiki
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first described an early form of the technique in 1985 [104]. He subsequently 
described a modified technique using Taq polymerase and an automated thermocycler 
in 1988 [105].
In order to generate only the required product with the highest possible yield, a PCR 
reaction requires optimisation o f its conditions. The stage o f the reaction during 
which the primers anneal is most susceptible to variations in conditions and most 
amenable to optimisation. Various conditions affect annealing. One o f the most 
important is temperature. As the temperature is reduced, the efficiency o f binding of 
the primers to the target DNA increases. However, the chances o f a primer binding 
to areas o f DNA that only partially match its sequence increase. This not only wastes 
primer but also gives rise to inappropriate products. The time allowed for annealing 
can also be important. It is necessary to allow enough time for all correct priming to 
take place but excessive times may increase the chances o f incorrect priming. The 
concentration o f magnesium ion (Mg2+) also affects the efficiency and specificity of 
primer annealing with higher concentrations reducing specificity. Mg2+ is also 
important as a co-factor for Taq polymerase (103). The amount o f primer is 
important. It is essential to have enough to ensure efficient annealing through to the 
late stages o f the reaction when the number o f target molecules has increased and 
some o f the primer has been used up. However, too much can increase the chances of 
inappropriate priming and can lead to the formation o f primer polymers. Similarly the 
concentration o f mixed deoxynucleotide triphosphates (dNTPS), the substrates o f the 
polymerase enzyme, is important. There must be sufficient present so that their 
concentration is not limiting in the late cycles but overly high concentrations can lead 
to nucleotide misincorporation.
The PCR reaction amplifies DNA. However, messenger RNA (mRNA) can be 
reverse transcribed to form a corresponding complementary DNA (cDNA) using a 
reverse transcriptase (RT) enzyme. These were originally derived from retroviruses 
and have intrinsic RNAase activity. Now RT enzymes are manufactured 
commercially from cloned viral genes and some such as Superscript (GibcoBRL) have 
the part o f the gene responsible for the RNAase activity removed. This ability to 
generate an amplifiable cDNA version o f an mRNA species means that the PCR
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reaction can be used to detect very small amounts of mRNA. These combined 
processes are referred to as RT-PCR.
Like the PCR reaction, the reverse transcription reaction also requires optimisation to 
ensure maximum efficiency. Reverse transcriptase, like DNA polymerase requires 
priming o f the target nucleic acid. This can be done either specifically using a cDNA 
oligonucleotide that anneals at the start of the mRNA sequence o f interest or non- 
specifically. Non-specific methods involve the use o f either random hexomers of 
DNA that bind at multiple sites on the RNA or Oligo-dT primers. Oligo-dT primers 
are deoxythymidine polymers 12-18 nucleotides long. These bind to the polyadenine 
tail o f mRNA. Non-specific methods are most commonly used. Oligo-dT priming 
has been found to yield less side products but may not work if the sequence o f interest 
is a long way from the polyadenine tail. Whilst RT enzymes such as Superscript are 
functional at 37°C, higher temperatures may increase yields or facilitate the 
transcription o f some mRNAs [106.].
6.1.2 Use of the RT-PCR Reaction for Quantitative Analysis of 
mRNA.
The ability o f RT-PCR to detect tiny amount o f RNA rapidly makes it very attractive 
as a method o f estimating mRNA in small tissue samples. The inherent amplification 
makes it much more sensitive than Northern blotting. The first reported attempt to 
use RT-PCR for quantification of mRNA was described by Chelly in 1988 [105]. He 
compared expression o f the scarce dystophin gene product by comparing it to the 
expression o f aldolase mRNA.
Due to the exponential nature o f amplification in the PCR reaction, small changes in 
reaction conditions can result in large changes in the amount o f product generated. 
Furthermore, in the latter stages of a reaction, depletion o f reaction components, 
accumulation o f products and decreased enzyme efficiency, lead to plateauing of the 
amplification [108]. For PCR to be used quantitatively it is necessary that the 
reaction remains in the exponential phase and does not plateau across the full range of
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template concentrations being assessed. Optimisation of the assay facilitates its 
quantitative use in two ways. The maximum possible amount o f product is generated 
at each cycle thus minimising the number of cycles necessary for product detection 
and the reaction may run for more cycles before reaching plateau.
Whilst large changes in RNA expression can been measured without comparison to 
controls in experimental systems [109] most studies employ some control component. 
This may either take the form of another gene product that is expressed at a constant 
level in the tissues being studied, or on external template which combines with the 
same primers as the species being measured [110]. The use o f different primers to 
carry out two different PCR primers in the same tube has been commonly employed 
[107,111] but creates several problems [112]. Having another PCR reaction 
competing for products and accumulating reaction products can inhibit the 
amplification o f the main target molecule. Unless the standard is present in similar a 
similar concentration to the target one reaction may plateau before the other so 
limiting the amount o f amplification o f the less abundant target. This limits the 
sensitivity o f measurement o f low copy mRNA species when common housekeeper 
genes such as p-actin are used as controls. The reaction conditions must be a 
compromise between those that are optimal for the two targets. Therefore not only is 
the efficiency o f amplification of both targets compromised but any variation in 
reaction conditions may shift the balance in favour of one or other target so producing 
an alteration in the target to control ratio. Many workers have addressed the problem 
of different reaction conditions by using a control target that has the same primer 
binding sites as the target molecule. The control should be distinguishable either by a 
small size difference or by inclusion of a different endonuclease restriction site. This 
control mRNA can be either produced synthetically [111] or mRNA from a different 
species used [56,114]. The inclusion o f a target with the same primer-binding site 
results in competition for primers. The rate o f amplification o f one target is therefore 
greatly influenced by the concentration o f the other [112]. This is overcome by a 
technique called competitive PCR. This involves running a series o f PCR reactions 
containing a fixed amount o f the unknown target molecule and varying amounts of the 
control. As the concentration of the control increases, more o f its product and less of 
the unknown target product is generated. By plotting the amount of both products
76
generated against the concentration of the control target, the concentration o f the 
unknown target can be extrapolated. A problem arises when using this technique to 
measure mRNA. If the concentration o f cDNA in a reversed transcribed sample is 
measured against a cDNA control, this does not control for the efficiency o f the 
reverse transcription reaction. To overcome this a titration of an mRNA standard can 
be used. However, this requires both a reverse transcription and PCR reaction to be 
carried out for each different standard concentration. Depending on the range of 
unknown RNA concentrations this may require up to ten RT and PCR reactions for 
each unknown sample. This approach was used to measure the expression o f VEGF 
by Yonekura et al [56]. An alternative approach is to carry out a single RT reaction 
then use competitive PCR to measure the concentration o f both the unknown mRNA 
and a control “housekeeper” gene product such as p-actin. This has the advantage of 
controlling for any errors in the estimation o f the amount o f mRNA present in each 
sample. However, it requires two sets of competitive PCR titrations to be carried out 
for each sample so necessitating a large number o f PCR reactions [115]. The 
competitive PCR approach is an accurate way of measuring mRNA concentrations in 
experiments that require estimation of a fairly small numbers o f samples. However if 
a large number o f tissue samples are to be screened for either clinical or research 
purposes, the large number of PCR reactions required make it expensive and 
laborious.
A simpler approach would be to reverse transcribe the mRNA from each sample then 
amplify both the cDNA to be measured and the control gene product in separate 
reactions. This eliminates the problems outlined above o f running two PCR reactions 
in the tube. Replicates are required to allow for variations in reaction efficiency 
between PCR reactions in different tubes but this still requires far fewer PCR 
reactions than the competitive method. Duplaa et al described this approach in 1993 
[116]. It has been suggested that the variation between different tubes in the PCR 
reactions presents a problem with this technique [113]. However, since the 
completion o f this word described in this thesis, it has been successfully employed by 
several groups for the measurement o f VEGF mRNA in breast [87,88] and other 
tissues [68,117].
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6.2 Methods
6.2.1 Outline of Method.
A variation on technique of separate amplification o f standards, described above was 
used in this project. Since GAPDH may be upregulated in some breast tumours [98] 
P-actin was used as standard. RNA from tissues was reverse transcribed. Samples of 
the resulting cDNA mixture were then used in separate PCR reactions to amplify 
VEGF and p-actin. A sample o f standard RNA extracted from the T47D breast 
cancer derived cell line was included with each batch o f reverse transcriptions. The 
cDNA derived from reverse transcription of this standard RNA was serially diluted 
and a sample o f each dilution was run with tissue-derived samples in both the VEGF 
and P-actin PCR reaction. The PCR products derived from both the tissues samples 
and serially diluted cell line cDNA was run on an agarose gel in the presence of 
ethidium bromide. This intercalates in the DNA helix and fluoresces when exposed to 
ultraviolet light. The luminescence of the band is proportional to its DNA content. 
Molecular weight markers were also run on each gel to ensure that the molecular 
weight o f the product was consistent with expected product size. Each gel was 
imaged using the BioRad Geldoc system. The product bands from the serially diluted 
cell line cDNA were used by the system’s “Molecular Analyst / PC” software to 
generate a standard curve. The relative concentrations o f the VEGF or P-actin PCR 
products on each gel were then derived by linear regression from this curve by the 
software.
The standard curve ensures the linearity o f amplification, luminescence and image 
acquisition for each gel. It also corrects for variations between different batches of 
PCR reactions. Therefore, if variations in master mix composition or performance of 
the thermocycler resulted in the VEGF reactions being more or less efficient relative 
to the p-actin reactions, comparison with standard mRNA processed in parallel 
compensates for this source o f error. To control for variations in the amount of 
mRNA in different samples and any variations between reverse transcription reactions, 
the VEGF to P-actin ratio was calculated for each sample. Since this assay does not
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include an external standard o f a known quantity o f VEGF mRNA the values it 
generates are relative rather than absolute. This was deemed appropriate for the 
purposes o f this study
Figure 5. The Gel Doc Gel Imaging System. (Photo reproduced with permission from BioKad Corp.)
The p-actin actin primers were as follows:
5’ ATGCCATCCTGCGTCTGGACCTGGC (location 2310-2334)
3 ’ AGCATTTGCGGTGCACGATGGAGGG (location 3127-3103)
They had been synthesised by Oswel DNA, Edinburgh and previously used for PCR in 
the Department o f Surgery, Western Infirmary, Glasgow.
In order to  generate a cDNA template for amplification for PCR, it was necessary to 
use the reverse transcription reaction. This generates a single strand o f DNA using 
messenger RNA as a template. Superscript RNAase H reverse transcriptase 
(GibcoBRL) was used to carry out the reverse transcription reactions. This is 
produced from a cloned M-MLV RT gene from which the RNAase II sequence has 
been deleted, thus reducing the RNAase activity to undetectable levels [106],
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Extensive effort was given to the optimisation o f both the PCR and reverse 
transcription reactions and the verification of the linearity o f amplification achieved by 
these.
The assay was used to estimate VEGF mRNA expression in several samples derived 
from archival breast tumours. This expression was then compared to the pathological 
and clinical data for these patients. No pathological or clinical data was obtained 
prior to making the VEGF measurements.
6.2.2 Tissue Culture
Two cell lines were used in this work. These were T47D (ATCC HTB-133) [118] 
and MCF7 (ATCC HTB-22) [119]. These grow as adherent monolayers. Both had 
been isolated from pleural effusions o f patients with breast cancer. Both lines were 
purchased directly from the American Type Culture Collection (ATCC), Manssasa. 
Both were cultured in accordance with the recommendations in the relevant ATCC 
data sheets. T-47D cells were propagated in RPMI 1640 medium supplemented with 
2mM L-glutamine, 1.5g/L sodium bicarbonate, 4.5g/l glucose, lOmM HEPES ImM 
sodium pyruvate, 0.2units/ml insulin and 10% foetal calf serum. The medium used for 
the MCF7 cells was Eagle’s minimal essential medium with Earle’s BSS supplemented 
with 2mM L-glutamine 1.5g/l sodium bicarbonate, O.lmM non-essential amino acids, 
ImM sodium pyruvate, 0.01 mg/ml insulin and 10% foetal calf serum. Cells were 
grown in 25cm2 Nunclon tissue culture flasks (Nunc). Medium was changed three 
times weekly and cells were subcultured with a 1:5 dilution when confluent. Cells 
were mobilised for subculture and harvesting by rinsing with 0.25% trypsin with 
0.03% EDTA. Stocks of cells were frozen in liquid nitrogen in culture medium 
containing 5% DMSO.
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6.2.3 Extraction of RNA
RNA extraction from both cultured cells and breast tissue was carried out using 
TRIzol reagent (Total RNA Isolation reagent) (Life Technologies Inc). This is a 
mono-phasic solution o f phenol and guanidine isothiocyananate.
The technique for homogenisation of the sample was different for cultured cells and 
tissues but the remaining stages o f the process were identical.
6.2.4 Homogenisation of cultured cells
A volume TRIzol reagent corresponding to 1ml per 10cm 2 o f culture surface area 
was added to tissue culture flasks containing confluent monolayers o f cells. Cells 
were detached from the surface o f the flask with a disposable cell scraper and the 
suspension pipetted to break up clusters o f cells. 1ml aliquots o f the suspension were 
placed in centrifuge tubes.
6.3.5 Homogenisation of tissues
Pieces o f breast tissue that had been stored in liquid nitrogen were used. The pieces 
were fragmented with a steel tissue crusher (piston and cylinder) in a bath of liquid 
nitrogen. The fragments were then transferred to a clay pestle chilled in a bath of 
liquid nitrogen and ground to a fine powder.
Approximately 75mg of this powder was place into centrifuge tubes and 1ml of 
TRIzol reagent added to each tube. The contents were pipetted to suspend the 
powder.
The following steps were the same regardless o f whether the material originated from 
cultured cells or tissue.
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6.2.6 Phase Separation
The homogenised samples were incubated for five minutes at room temperature to 
dissociate the nucleoprotein complexes and 0.2 ml o f chloroform was then added to 
each tube. The tubes were shaken vigorously by hand, for fifteen seconds then left to 
stand at room temperature for three minutes. They were then centrifuged at 12000 g 
for fifteen minutes in a refrigerated centrifuge at 4°C.The upper aqueous phase in each 
tube which contained the RNA was then carefully withdrawn and transferred to a 
fresh tube.
6.2.7 Precipitation and Washing of RNA
RNA was precipitated by adding 0.5ml o f isopropanol to each tube and allowing it to 
stand at room temperature for ten minutes. The tubes were then centrifuged at 
12000g for ten minutes at 4°C. The supernatant was withdrawn and the pellet in each 
tube washed 1ml o f 75% ethanol at 4°C. The samples were mixed and centrifuged at 
7500g for five minutes at 4°C. The ethanol was removed and the pellets air-dried. 
The pellets were then dissolved in DEPC treated water by incubating them at 55°C for 
ten minutes.
6.2.8 Reverse Transcription of RNA
In order to prepare a solution o f T47D cDNA for use in optimisation o f the PCR 
assay, RNA extracted from this cell line was reverse transcribed. The nucleic acid 
concentration o f the RNA was determined by spectrophotometry. A volume 
equivalent to 15pg o f total RNA was measured and divided equally between each of 
three reverse transcription reactions. Each reaction contained 5 pi o f First Strand 
Buffer (Gibco), 5 pi o f 0.1M DTT, 1.5 pi o f 500 pg 01igo(dT)i2-i8 (Gibco), 5 pi of  
lOmM mixed dNTP 2 pi of RNAguard RNAase inhibitor (Pharmacia) and 4 pi 
(800U) of Superscript RNAase H reverse transcriptase (Gibco) made up to a total 
volume of 50 pi. The products o f the three reaction mixtures were pooled.
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6.2.9 PCR and Image analysis.
The principle o f the PCR reaction has been described above. For each stage o f the 
optimisation o f the assay all components of the reaction other than that being varied 
were prepared in a master mix to ensure uniformity between reactions. The total 
volume of each reaction mix was 50pl. Reactions were overlayed with 20ul of 
mineral oil to prevent evaporation. Reactions were run on automated thermocycler 
blocks. Gel electrophoresis was carried out in the presence o f ethidium bromide as 
has been described in section 2.2.3 above. Gels were than placed in the Geldoc 
(Biorad) imaging system and a digital image o f the gel acquired. This was then 
processed using the system’s Molecular Analyst/PC v l.2  software. The software 
generates a value for the “adjusted volume” (counts x mm2 ) o f each band on the gel 
which corresponds to the relative amount o f DNA in each band. This allows 
comparison between individual bands on the same gel.
6.3 Results and variations in PCR conditions.
6.3.1 Preliminary assessment of linearity and effect of cycle number.
Initially an attempt was made to determine whether a linear relationship existed 
between starting template cDNA concentration & the amount o f PCR product and 
through how many cycles o f PCR this was maintained.
The template used was cDNA that had been prepared by reverse transcription of RNA 
extracted from the T47D breast tumour cell line.
A l | L i l  sample o f cDNA solution was serially diluted to give 1/2, 1/4, 1/8, 1/16, 1/32, 
1/64 and 1/128 pi o f cDNA in a total volume of lOpl per tube.
A master mix was prepared in accordance with the standard protocol in use in the 
laboratory. This contained PCR buffer (Gibco) at working strength, 1.5 mM MgCl2
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(Gibco), mixed dNTPs (0.8 pi per 50pl reaction), lOOng o f 5’ and 3' VEGF primers 
and Taq (Gibco) lunit per 50ul reaction in a volume equivalent to 40ul per reaction. 
This was added to each of the diluted template samples to give a volume o f 50pl.
Thermal cycler parameters were similar to those in routine use in this laboratory.
These were:
94° C for five minutes
Cycles of
94° C for thirty seconds 
58° C for thirty seconds 
72° C for thirty seconds
72°C for five minutes.
PCR was carried out for 25 cycles. A lOpl sample was then withdrawn from each 
tube. The reaction was continued for a further 5 cycles. 10 pi was withdrawn and the 
reaction continued for a further 5 cycles. Samples taken after 25, 30 and 35 cycles 
were electrophoresed on a 1.2% agarose gel along with a lOObp DNA molecular 
weight marker ladder.
The gel was analysed using the GelDoc acquisition and analysis system (Biorad) using 
volume analysis for each band with subtraction of both general and local backgrounds.
Only after 35 cycles were bands clearly visible though faint traces were seen with the 
higher template concentrations after 30 cycles. In the samples measured after 35 
cycles, bands corresponding to l/64pl or less o f template were barely visible on either 
photographs or electronically captured images of the gels. Of the remaining reactions, 
that from the l/4pl of template reaction gave no band and from the reaction with 
1/16pl yielded a smear on the gel.
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The DNA concentrations in the four visible bands from the samples taken after 35 
cycles were estimated by volume analysis using the molecular analyst software 
(Biorad). When plotted against the relative concentration of template a straight line 
was obtained (r =1).
Amount of Template Adj Volume 
(tl of T47d cDNA) (counts x rrntf)
1 684
0.5 338
0.125 84
00312 11
Table 2. Preliminary assessment of linearity
Amount of PCR Product v Template
(35 cycles)
800
700
600
|  500
r  400
300
200
100
0 0.2 0.4 0.6 0.8 1 1.2
Amount of template (ul)
Figure 6 Preliminary assessment of linearity
Although there were only four usable data points, these were consistent with linear 
amplification having occurred.
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6.3.2 Effect of Annealing Temperature.
Higher temperatures increase the specificity o f annealing, reducing the chance o f non­
specific binding with consequent generation o f extraneous product. However, 
excessive temperatures lead to poor annealing and may therefore compromise reaction 
efficiency. This experiment was designed to determine whether a lower annealing 
temperature would generate a higher reaction yield.
Sufficient master mix for four PCR reactions was prepared as above. Fifty microlitre 
reactions containing lp l o f T47D cDNA template were set up. Two reactions were 
placed on each block o f the thermocycler and the programs below were run.
1)
94°C for 5 minutes
2)
94°C for 5 minutes
35 cycles of 
94°C for thirty seconds 
55°C for thirty seconds 
72°C for thirty seconds
94°C for thirty seconds 
58°C for thirty seconds 
72°C for thirty seconds
72°C for five minutes. 72° C for five minutes
The samples were run on an ethidium bromide agarose gel and analysed using the 
GelDoc system as before.
Annealing Adj Volume mean S . O
Temp °C counts x mm2
55°C 2315
1987 2151 232
58°C 2398
2371 2385 19
Table 3. Effect of annealing temperature
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Effect of Annealing Temperature
Annealing Temperature
Figure 7. Effect of annealing temperature
Lowering the reaction temperature did not appear to result in an increased yield. It 
would not appear that the higher temperature was inhibiting annealing. No extra 
bands were seen at either temperature suggesting that annealing specificity was 
sufficiently high. It was therefore decided to  continue to use 58°C as the annealing
temperature.
6.3.3 Effect of Cycle Duration
Since two o f the PCR reactions in the first experiment failed to yield a band when 
expected to do so, the possibility existed that there was a variation in the temperatures 
that the reactions were subjected to either due to differences in heat conduction o f the 
tubes or the heating o f the block. This is a particular problem if the cycle times are 
short so that the tubes do not have sufficient time to equilibrate to the set temperature 
and the reaction may not have time to complete once the correct temperature has been
87
reached. Such inconsistencies should be minimised by increasing the times spent at 
each temperature during the cycle. By ensuring that the reaction always goes to 
completion it was hoped that this might increase the overall efficiency o f the reaction 
as well as minimising discrepancies between individual tubes.
Again, two pairs o f reaction tubes with 0.5pl o f T47D cDNA solution and all other 
components as above were set up. Using the satellite block o f the thermal cycler for 
one pair, the PCR reaction was carried out under the following cycle settings
Pair 1 Pair 2
94°C for 5 mins 94°C for 5 mins
35 cycles of: 35 cycles of:
94°C for 30 secs 
58°C for 30 secs 
72°C for 30 secs
94°C for 1 min 
58°C for 1 min 
72°C for 2 mins
72°C for 5 minutes 72°C for 5 minutes
lOpl o f product from each tube was electrophoresed on a small 1.2% agarose gel as 
before. The gel was imaged with the GelDoc system and the bands analysed by 
volume analysis.
Cycle Oufation Adj Volume mean S>0
counts x mm2
Short Cycle 13645
11744 12695 1344
Long Cycle 16879
18689 17784 1280
Table 4. Effect of cycle duration
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Effect of Cycle Duration
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Figure 8. Effect of cycle duration
These results support the idea that using longer cycle times to ensure that each phase 
o f the reaction consistently reaches completion does indeed increase the yield. The 
longer cycle durations were therefore used in subsequent work.
6.3.4 Optimisation of Reaction Mix Components.
As has been discussed in the introduction, the concentrations o f  the individual 
components o f  the PCR reaction are important to the efficiency o f  the reaction and to 
amplification linearity. In this set o f  experiments, the effect o f varying Mg2" 
concentration, Taq concentration and primer concentration was assessed. The other 
components o f  the reaction were used in the same concentrations as in the previous 
experiments.
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For each experiment, a master mix was prepared containing all the reaction 
components except the one that was being titrated. PCR reactions were then carried 
out using the long cycle thermocycler setting described in the last experiment.
The settings were:
94°C for five minutes
35 cycles of:
94°C for one minute 
58°C for one minute 
72°C for two minutes
72 C for five minutes
The products of each reaction were analysed using the GelDoc system as before.
The following range o f concentrations was used for each component.
Magnesium concentrations (2 units o f Taq + lOOng o f each primer per reaction)
ImM
1.5mM
2mM
2.5mM
3mM
3.5mM
4mM
Taq concentrations (1.5mM Mg and lOOng o f each primer)
1 unit per reaction
2 units per reaction
3 units per reaction
4 units per reaction
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Primer concentrations (1.5mM Mg and 2 units o f Taq per reaction)
1 OOng o f each primer 
200ng o f each primer 
3OOng o f each primer.
Mg Cone 
mM
re! conc. m ean S.D 
(counts x mm2)
1 699
1036 867.5 238.295
1.5 1194
1191 1192.5 2.12132
2 1105
1034 1069.5 50.20458
2.5 1124
1192 1158 48.08326
3 1167
1167 1167 0
3.5 646
857 751.5 149.1995
4 935
696 815.5 168.9985
Table 5 Effect of magnesium concentration
Effect of Mg Concentration.
1400
E 1200
1000
800
600
400 --
200  -
0 1 2 3 4 5
Mg co n e  (mM)
Figure 9 Effect of magnesium concentration
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Amount of taq 
(unit / tube)
Rei, oonc
(COtJ
mean S*D 
ints x mm2)
1 1094
1175 1134.5 57.28
2 1194
1191 1192.5 2.12
3 1622
2149 1885.5 372.65
4 648
979 813.5 234.05
Table 6 Effect of Taq concentration
Eff ec t  of  Taq C o n c e n t r a t i o n
2 500
Figure 10. Effect of Taq concentration
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A m o u n t o f  E a c h  P r i m e r  
ng p e r  r e a c t i o n
R e i C o n c .  M e a n  S. D  
c o u n t s  x m m 2
1 0 0 1 1 9 4
1 1 9 1  1 1 9 2 . 5  2 . 1 2
2 0 0 9 0 9
5 0 3  7 0 6  2 8 7 . 0 9
3 0 0 98  8
1 0 0 9  9 9 8 . 5  1 4 . 8 5
Table 7. Effect of primer concentration
Effect of Primer Concentration
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Figure 11. Effect of primer concentration
It appeared from these results that raising the concentration o f MgCl2 above 1.5mM 
gave no benefit in reaction efficiency. There appeared to be a large plateau in reaction 
efficiency with no substantial change in efficiency until the concentration was raised 
above 3mM. At higher concentrations the efficiency fell, presumably due to non­
specific priming and indeed some smearing was seen on the gel. By using a 
concentration at the low end o f this plateau, the possibility o f non-specific priming 
was lowered. There appeared to be no benefit obtainable from increasing primer
concentrations so it was unlikely that these were limiting the amount o f product 
generated in these reactions.
There did however appear to be significant benefit obtained from increasing the 
concentration of Taq with an increase in efficiency o f 66% obtained by increasing the 
concentration from 1 to 3 units. The variations between duplicate reactions were 
however high and it was not clear why the efficiency apparently fell when four units of 
Taq per reaction were used. It was felt therefore that the possible benefit of an 
increased Taq concentration merited further investigation
6.3.5 Effect of Prolonging Extension time.
The need for such high concentrations o f Taq for optimal efficiency raised the 
possibility that the reaction was still time limited. It seemed possible that if a longer 
extension phase was used that less Taq might be required. Therefore the effect of 
increasing the extension time from two to five minutes was investigated. Reactions 
were set up as before. Two pairs o f reactions containing lunit o f Taq and two 
containing 3 units were prepared. One pair with each Taq concentration were 
subjected to the following thermocycle programs
Program 1 Program 2
94°C for five minutes 94°C for five minutes
35 cycles of:
94°C for one minute 
58°C for one minute 
72°C for two minutes
35 cycles of:
94°C for one minute 
58°C for one minute 
72°C for five minutes
72°C for five minutes 72°C for five minutes
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Amount Extension RelConc. Mean 8 .0  
of Taq time counts x mm2
1 unit
per reaction
1 min 4090
4326 4208 166
5 mins 5347
5371 5359 17
3 units 
per reaction
t min 4777
4559 4668 154
5 mins 4279
4554 4416.5 194
Table 8 Combined effect of Taq and extension time
At low Taq concentration it appeared that prolonging the extension time did indeed 
increase yield. However at the higher Taq concentration, a prolonged extension time 
did not lead to a higher yield.
6.3.6 Effect of Incremental Extension Time
It was possible that the finding o f poor yield with the combination o f a high Taq 
concentration and long extension time was due to the generation o f inappropriate 
non-specific product. Since this is most likely to occur during the earlier cycles when 
concentrations o f primers and Taq are highest it is possible that a short extension time 
might be appropriate at this stage. A longer time would be appropriate later in the 
reaction when Taq concentrations are lower due to degradation and primer 
concentrations are reduced. An experiment was designed to investigate this using 
incremental extension times.
A master mix was prepared and reactions were set up as before. Two pairs o f reaction 
tubes containing 1 unit o f taq and two containing 3 units were prepared. A pair with 
each Taq concentration was subjected to a thermocycler program that increased the 
extension time by five seconds each cycle starting with a two minute extension time 
progressing to a time o f just less than five minutes by the 35th cycle. The remaining
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two pairs were subjected to a program that gave an extension time o f five minutes 
throughout.
The thermocycler program parameters are shown below.
Program 1 Program 2
94°C for five minutes 94°C for five minutes
35 cycles of: 35 cycles of:
94°C for one minute 94°C for one minute
58° C for one minute 58°C for one minute
72°C for two mins in the first 72°C for five minutes
cycle increasing by five secs 
each cycle.
72°C for five minutes 72°C for five minutes
Amount 
of Taq
Extension
time
Ret Cone. Mean S.C 
counts x mm2
1 un it  
o f  T a q
5 m i n  e x t e n s i o n  
t i m e
1 5 4 3
1 6 6 7  1 6 0 5  8 8
i n c r e m e n t a l  
e x t e n s i o n  t i m e
6 7 3
8 0 3  7 3 8  9 2
3  u n i t s  
o f  T a q
5 m in  e x t e n s i o n  
t i m e
1 8 1 6
1 9 0 6  1 8 6 1  6 4
i n c r e m e n t a l  
extension time
1 6 2 6
1 1 7 9  1 4 0 3  3 1 6
Table 9. Effect of incremental extension time
These results did not show any benefit in using the incremental extension time over a 
steady five minute extension time with either 1 or 3 units o f Taq in the reactions. In 
this experiment there was a slightly higher product yield with 3 units o f Taq per
reaction.
6.3.7 Optimisation of Taq concentration
In order to elucidate further the effect o f Taq concentration with the longer, five 
minute extension time, a series o f reactions was set up with the following amounts o f 
Taq per tube:-
1.5 units
2 units
2.5 units
3 units
3.5 units
4 units
A master mix was prepared containing 1.5mM MgCh, and lOOng o f each primer per 
reaction. Thermocycler settings were the same as used previously with a constant five 
minute extension time
Units of Taq 
per reaction
Rel Cone. Mean S.D 
counts x mm2
1.5 3640
3670 3655 21.21
2 3878
3849 3864 20.51
2.5 3613
3662 3638 34.65
3 2840
3410 3125 403.05
3.5 2706
3211 2959 357.09
4 3216
3026 3121 134.35
Table 10 Optimisation of Taq concentration
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Figure 12. Optimisation of Taq concentration
In this experiment, the highest yield o f product occurred in the reactions with 2 units 
of Taq and there was no benefit seen in increasing beyond this. It appeared that with a 
j five minute extension time 2 units o f Taq were sufficient to allow the reaction to go as
near as possible to completion. This amount was therefore used in subsequent work.
I
j
6.3.8 Titration of dNTPs in the VEGF PCR reaction.
The dNTPs provide the building blocks for the synthesis o f cDNA in the PCR 
reaction. An experiment was set up to determine whether the availability o f dNTPs 
was limiting the generation o f product.
VEGF PCR reactions were set up as in the previous experiments, i.e. 2 units o f taq 
per reaction, lOOng o f each primer and MgCh concentration o f 1.5mM in a total 
volume of 50 pi. Duplicate reactions containing 4, 8, 12 or 16 and 20 pmol o f mixed 
dNTP were prepared. Reactions were run for 30 cycles o f PCR using the same 
reaction conditions as had been previously used i.e. 94°C denaturation, 58°C annealing 
and 72°C chain extension.
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dNTPs Adj Volume 
pmol/reaction(counts x mm2)
Mean Adj Volume 
(counts x mm1)
2610
2864 2737
8 2503
2905 2704
12 2304
1721 2013
475
810 643
20 0
0 0
Table 11. Effect of dNTP concentration
There did not appear to be any benefit in increasing the dNTP concentration. Instead 
higher dNTP reaction appeared to be associated with a decreased amount o f reaction 
product. This may be due to misincorporation o f bases leading to failure o f priming in 
subsequent cycles.
6.3.9 Optimisation of Cycle duration and Taq concentration for 
Actin PCR
Primers had previously been used in the laboratory, which amplify a fragment o f the 
(3-actin cDNA sequence. The reaction conditions being used with these primers were 
arbitrary and work was therefore directed at optimising these.
The primers were supplied by Oswel DNA, Edinburgh. The sequence o f these has 
been described in the introduction to this chapter
As a preliminary step to gauge the potential for optimisation, the effects o f using a 
longer cycle and a higher taq concentration as used in the VEGF PCR reactions were 
compared to the protocol previously used in the laboratory which used 1 unit o f Taq 
per reaction consisted o f 30 seconds o f denaturation, annealing and extension in each
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Reactions were therefore set up using ether one or two units o f Taq. Two 
thermocycler programs were used, a short cycle with thirty second steps as before 
and a long cycle as used for the VEGF assay consisting o f one minute denaturation, 
one minute annealing and five minutes extension in each cycle. The reaction 
conditions were otherwise as before i.e. PCR buffer (Gibco) at working strength, 1.5 
mM MgCl2 (Gibco), mixed dNTPs (0.8 pi (8pmol) per 50pl reaction). 0.5pi o f lOuM 
sense and antisense primers were added.
Amount \ Cycle i Adj Volume Ij Mean S.D
of Taq i duration ! counts x mm2
\ Short 6007 i
I cycle 8235 I 7121 i 1575
1 unit taq
per reaction ?Long 8221 3
I cycle 8365 \ 8293 ; 102
I Short
2 units taq ji cycle 9596 I 9045 I 780
per reaction 8493 \
SLong ...............8 0 9 1 ? ...........
I...................... ; cycle 9227 ; 8659 : 803
Table 12. Effect of Taq and cycle duration on actin PCR
It appeared from these results that using two rather than one unit o f taq per reaction 
may be of benefit in increasing the yield of the PCR reaction. No benefit was 
however seen in this experiment from increasing cycle times.
6.3.10 Optimisation of Magnesium Concentration Actin PCR
The concentration o f magnesium in the PCR reaction is critical to the specificity and 
yield of the reaction. Therefore an experiment was set up to determine the optimal 
magnesium concentration for the actin PCR. The temperature at which annealing is 
carried out is linked to the magnesium concentration in that any non-specific binding 
that occurs at higher magnesium concentrations may be potentially be prevented by 
increasing the annealing temperature. Therefore, the titration was carried out at 65°C 
as well as 60°C. Based on the result o f the previous experiment, 2 units o f Taq were
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used in each reaction. A range of magnesium concentrations from 1 to 4 mM was 
used. The master mix was otherwise as before.
PCR was carried out as follows: 
94° C for five minutes
Cycles of
94° C for thirty seconds
60°C or 65°C for thirty seconds 
72° C for thirty seconds
72°C for five minutes.
Samples were run on an ethidium bromide gel and analysed with the GelDoc system 
| as before.
i
!
60 degrees 65 degrees
Mg Cone. rel. vol of ban< mean S.D rel. vol of ban( mean S.D
(mM) counts x mm2 counts x mm2
1.0 3523 3630
3763 3643 170 2682 3156 670
1.5 5092 5214
5497 5295 286 4109 4662 781
2.0 1924 3235
3671 2798 1235 3324 3280 63
2.5 1264 1107
1015 1140 176 933 1020 123
3.0 464 183
527 496 45 237 210 38
3.5 412 115
242 327 120 174 145 42
4.0 159 0
47 103 79 201 101 142
Table 13. Relationship between Magnesium Concentration and Reaction Yield
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Figure 13. Relationship between Magnesium Concentration and Reaction Yield
From this experiment, the optimal reaction yield would appear to occur at a 
magnesium concentration of 1.5mM with a temperature o f 60°C. Since these were 
the conditions already being employed, no improvement o f reaction conditions could 
be made from the information obtained in this experiment.
6.3.11 Titration of Primers
The effect o f varying the concentration of the PCR primers was examined to 
determine whether this might be a limiting factor in the reaction and whether changing 
this might improve reaction yield. Amounts from 5 to 40 pmol of each primer were 
tested. Reactions were otherwise as described previously. Thermocycler settings 
were as before and PCR was run over 30 cycles.
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Duplicate reactions or each primer concentration 
Figure 14. Primer titration- Photograph of gel
Amount of each primer Adj Volume 
(pmol) (counts x mm2)
Mean Adj Volume 
(counts x mm2)
4938
5241 5090
10 4995
5447 5221
15 6056
6203 6130
20 5521
5693 5607
25 6090
5280 5685
30 6059
6010 6035
13
6740 NA
40 6711
58 NA
Table 14. Effect of titration of primers on actin PCR
These results suggested that some improvement in reaction yield could be achieved by 
increasing primer concentrations in the reactions. These improvements were however 
modest and did not suggest that primer shortage was a major constraint on the 
reactions. M oreover when 15 pmol or more o f each primer was added the emergence
of extra low molecular weight bands was seen. By comparison, with a plot o f 
migration distance o f the 100 base pair markers, it is apparent that these extra bands 
are approximately 50, 100 and 150 base pairs compared with the main actin band of 
approximately 600 base pairs. Given that the primers are 24 bases in length, these 
extra bands may represent either primer polymers or mispriming. The appearances of 
this phenomenon at high primer concentrations therefore limits the increase that can 
be made. However given that increasing primer concentration did seem to be o f some 
benefit, an increase from 5 to lOpmol o f  each primer per reaction was made in 
subsequent experiments.
6.3.12 Titration of dNTPs.
The effect o f making two and three fold increases in the dNTP concentration was 
examined.
Reactions were again set up as above. The increase in the amount o f each primer in 
each reaction from 5 to lOpmol was implemented. Duplicate reactions containing 8, 
12 or 16 pmol o f dNTPs were set up. Thermocycler settings were as before and 30 
cycles o f PCR were carried out.
dNTPs Adj Volume Mean Adj Volume
pmol/reaction (counts x mm2) (counts x mm2)
8 23359
21937 22648
12 29364
28683 29024
16 28617
23010 25814
Table 15. Effect of dNTP concentration in the actin PCR
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These results suggested that an increase in the amount o f dNTP to 12 pmol per 
reaction did indeed increase the amount of product generated. However a further 
increase yielded no apparent additional benefit. Therefore in subsequent experiments 
the amount of dNTPs in each reaction was increased.
6.3.13 Effect of Length of Cycle Steps in the Actin PCR Reaction
In the preceding experiments, it can be seen that there have been considerable 
differences between the amounts o f product from duplicate PCR reactions although 
these were set up by dividing a common substrate mix. This suggests that there was 
some difference in efficiency o f the PCR reaction between tubes. It was felt that the 
thirty seconds allowed for each step o f the reaction might not always be enough to let 
the reaction go to completion. Therefore the effect of doubling the step times on both 
the reaction yield and the variation in yield between tubes was investigated.
| Actin PCR reactions were set up as before with o f lOpmol o f each primer and 12pmol
i
| o f dNTPs per reaction. Twelve 50pl reactions were prepared and six placed in each
of two thermocycler blocks.
i
i
|
In both blocks, the tubes were heated to 94°C for five minutes. This was then 
followed by 30 cycles with 94°C denaturation, 60°C annealing and 72°C extension 
steps. In the first block these steps were of thirty seconds duration. In the second 
block, each step lasted sixty seconds. Finally both blocks were held at 72°C for five 
minutes. Products were analysed as before using agarose gel electrophoresis and the 
GelDoc system. The mean and standard deviation for each group o f six samples was 
calculated.
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Therroocycler
Settings
Product 
Adj Volume Mean S.D 
counts x mm4
30 second 
thermocycler steps
8767
11804
12074
12075 
11599
12110 11405 1308
60 second 
thermocycler steps
11823
12290
11688
13015
11816
11802 12072 507
Table 16 Effect of cycle step duration in actin PCR
From these results, it appeared that increasing the time for each step o f the reaction 
from thirty seconds to one minute not only leads to a slight improvement in reaction 
yield but, more importantly decreased the variation between reactions, as shown by 
the decrease in the standard deviation. The reaction time for each step o f the actin 
PCR was therefore increased to one minute.
6.3.14 Assessment of linearity of VEGF PCR under modified 
reaction conditions
Initially, in section 6.3.1, a linear relationship was demonstrated between the amount 
o f template present at the start o f the reaction and the amount o f product after 35 
cycles o f PCR. However, as changes had been made to the reaction times and the 
amount o f Taq, it was necessary to test whether this linearity remained.
A serial dilution o f cDNA from the T47D line was prepared to give reactions 
containing 1, 1/2, 1/4, 1/8, 1/16, 1/32, 1/64, 1/128 pi o f the cDNA solution. A 
master mix o f the other reaction components was prepared and aliquoted into each 
tube so that each reaction contained 2 units o f taq, 8mol o f dNTPs, lOOng o f each 
primer and an M gCb concentration o f 1.5mM.
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The PCR reaction was carried out as before for 30 cycles i.e,
94°C for five minutes
30 cycles o f 
94°C for one minute 
58°C for one minute 
72°C for five minutes
72°C for five minutes.
A 1 Ojal sample was then withdrawn from each tube and a further 5 cycles o f the PCR 
reaction carried out.
Amount of cDNA 
per reaction (pi)
Amount of Product 
Rel. vol of band
30 cycles 35 cycles
1 751 3138
0.5 580 3183
0.25 250 2766
0.125 121 1459
0.0625 68 930
0.03425 15 628
0.015625 3 239
0.0078125 5 289
Table 17. Test of linearity at 30 and 35 cycles
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Figure 15. Test of linearity at 30 and 35 cycles
It can be seen from the graph that after 30 cycles a linear relationship appeared to 
exist between the amount o f template cDNA and the amount o f product formed with 
less than 0.5 pi o f template cDNA solution per reaction. The yield o f product after 35 
cycles was higher but a plateau in the product verus template plot was seen when the 
amount o f template exceeded 0.2pl o f mRNA solution. This would potentially limit 
the range o f RNA concentrations over which the reaction was usable. Further 
reactions were therefore set up to assess whether a better compromise between 
product yield and linearity could be achieved between the 30 and 35 cycle reactions 
used above.
Serial dilutions o f T47D cDNA were prepared and aliquoted into tubes to give 4 sets 
of reactions each containing the following range o f cDNA amounts:- 4,2,1,1/2, 
1/4,1/8, 1/16,1/32 nl.
The VEGF PCR master mix was the same as previously used. VEGF PCR was run 
for 32 and 33 cycles using one minute denaturing and annealing steps and five minute 
extension. The composition o f the actin master mix reflected the modifications 
derived from previous experiments i.e. 2 units o f taq per reaction, 12 pMol o f dNTPs, 
lOOng o f each primer and a MgCh concentration o f 1.5mM. Actin PCR was run for 
26 and 28 cycles using one minute denaturing, annealing & extension steps. Relative
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volumes of the bands on the ethidium bromide gel were derived from the GelDoc 
system and plotted against the amount of template in each reaction.
VEGF
Amount of
Template
u(/reactton
Adj Volume 
counts x mm2 
32 cycles 33 cycles
I I 4 717 2563
2 256 985
1 135 561
0.5 111 198
0.25 93 51
0.125 24 39
0 0625 1 15
0.03125 0 3
Table 18. Linearity test of VEGF PCR 32 and 33 cycles
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Figure 16. Linearity test of VEGF PCR 32 and 33 cycles
It appeared from the data above that VEGF PCR can be carried out up to 33 cycles 
with preservation of linearity over a wide range of reaction conditions.
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6.3.15 Assessment of linearity of Actin PCR under modified reaction 
conditions
An attempt was made to determine how many cycles the actin PCR could be run for 
whilst preserving the linearity of the product v template curve.
The composition of the actin master mix reflected the modifications derived from 
previous experiments i.e. 2 units of taq per reaction, 12 pMol of dNTPs,lOOng of 
each primer and a MgC12 concentration of 1,5mM. Actin PCR was run for 26 and 28 
cycles using 1 minute denaturing, annealing & extension steps. Relative volumes of 
the bands on the ethidium bromide gel were derived from the GelDoc system and 
plotted against the amount of template in each reaction.
Actin
Amount of
Template Adj Volume
ul/reaction counts x mm*
26 28
cycles cycles
4 6675 7624
2 6400 8361
1 • . - v ^ : 5774 8567
0.5 5535 8499
0.25 5592 7649
0.125 4540 6235
0.0625 4239 5372
0.03125 3047 3271
Table 19 Linearity test of actin PCR 26 and 28 cycles
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Figure 17 Linearity test of actin PCR 26 and 28 cycles.
There was a rapid rise in the amount o f actin product generated with increasing 
template quantities but at both 36 and 28 cycles a plateau was rapidly reached. This 
| suggested that a smaller number o f PCR cycles may be appropriate to extend the
J
I usable range o f template mRNA concentrations. As the ultimate aim was to achieveI
linearity o f the entire reverse transcription and PCR process so efforts were directed 
at optimising the reverse transcription step and then verifying linearity o f the entire 
process, rather than carrying out any further verification of the PCR linearity at this 
! stage.
|
6.4 Optimisation of the Reverse Transcription Reaction
6.4.1 Screening of samples for DNA contamination.
Before carrying out any work on the efficiency o f the reverse transcription reaction, it 
was important to ensure that no DNA was present in the RNA samples before reverse 
transcription. This could occur as a result of contamination o f the samples by 
genomic DNA.
Il l
Samples o f RNA which had been extracted from T47D cells were therefore screened. 
Five PCR reactions were set up for both VEGF and actin as described previously. 
One microgram o f T47D RNA was added to duplicate actin and VEGF reactions. A 
positive control reaction for both actin and VEGF was created by adding T47D 
cDNA to the fifth tube o f each set. PCR was then carried out for 35 cycles for VEFG 
and 25 cycles for actin. Products were run on an agarose ethidium bromide gel as 
previously.
Both control reactions yielded an appropriate product band on the gel. No product 
band was seen from any of the reactions containing only RNA.
This experiment demonstrated that the cell line derived RNA samples for use in the 
next part o f the work did not contain contaminating DNA detectable by either the 
VEGF or actin reactions despite using relatively large amounts o f RNA and larger 
than normal numbers o f amplification cycles.
6.4.2 Optimisation of Temperature and Time for the Reverse 
Transcription Reaction
Whilst the manufacturer’s protocol [106] suggests a reaction temperature of 37°C, it 
states that in some cases incubation at a higher temperature may increase yields or 
facilitate transcription of some mRNAs. The protocol recommends a reaction time of 
one hour. Since the time taken to achieve maximum yield may be linked to the 
reaction temperature, this experiment was designed to determine the effects both of 
raising reaction temperature and o f increasing reaction time on the yield o f VEGF and 
actin cDNAs from reverse transcription o f their mRNAs.
The protocol for reverse transcription was based on that given in the Superscript data 
sheet except no radioactive marker was added and RNAase inhibitor was added to the 
reactions to protect the RNA during the course o f the reaction. Pairs o f reactions 
were run under the following incubation conditions.
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1. 37 °C for one hour.
2. 37 °C for one and a half hours.
3. 45°C for one hour.
4. 45°C for one and a half hours.
Triplicate PCR reactions to amplify VEGF and |3-actin were set up containing lOpl of 
the products o f each reverse transcription reaction. There were therefore four PCR 
reactions for each set o f reverse transcription conditions.
VEGF Reverse Transcription
Reaction Ret Cone. Mean for each Overall Mean w m m m
Conditions (adj. vol) RT Reaction (mean adj vol)
3824
37°C 4257
1 hour 3915 3999
3220
4019
3708 3649 3824 349.9
4590
3560
37°C 3490 3880
1 1/2 hours 3253
3705
4087 3682 3781 482.9
2452
3186
45°C 2967 2868
1 hour 3800
4485
3724 4003 3436 716.5
1212
2027
45°C 2796 2012
1 1/2 hours 3186
2377
1223 2262 2137 811.8
Table 20. Optimisation of Temperature & Time for the Reverse Transcription Reaction
This experiment was repeated and similar results wereobtained. These results do not 
show any benefit in either increasing the reaction time or temperature. Instead when 
both reaction time and temperature were increased there was a marked detrimental
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effect in the amount of product formed which was confirmed when the experiment 
was repeated. This may be due to degradation of the cDNA in the final half hour of 
the RT reaction.
6.4.3 Effect of a Smaller Increase in Temperature.
It appeared from the last two experiments that raising the reaction temperature for the 
reverse transcription reaction to 45°C was not beneficial to reaction yields and may 
even be detrimental. Therefore an experiment was carried out to determine whether a 
smaller increase in temperature may enhance reaction efficiency.
Duplicate reverse transcription reactions were carried out as before at 37°C and 42°C. 
The products of these reactions were then amplified by PCR reactions for VEGF and 
actin as before with triplicates o f each PCR reaction carried out on the products of 
each RT reaction. Gel electrophoresis was carried out as before.
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Reaction Rel Cone. Mean for each Overall Mean S.D 
Conditions (adj. vol) RT Reaction mean adj vol)
VEGF
37°C 2299
1721
1579 1866
2185
3513
3505 3068 2467 851.4
42°C 1890
2776
2510 2392
1871
3270
2070 2404 2398 558.4
A ctid
37°C 3243
4138
4712 4031
5326
5170
2500 4332 4182 1120.6
42°C 3647
3379
4423 3816
6189
2570
5843 4867 4342 1429.8
Table 21. Effect of a Smaller Increase in Temperature
In this experiment it appeared that, in the reverse transcription, reaction there was no 
significant difference between the yields o f either actin or VEGF cDNA in those 
reactions run at 37°C and those at 42°C. Considering the preceding reverse 
transcription experiments overall, it appeared that the reactions generally reach 
optimum yield by one hour and that variations in temperature had little influence on 
the yield when the reactions are run for one hour. It was decided therefore to run 
future reverse transcription reactions for one hour and use 42°C as the reaction 
temperature.
6.4.4 Test of Linearity of Reverse Transcription Reaction by Serial 
Dilution
Eight reverse transcription reactions with serially halving quantities o f T47D RNA 
from 2 fig to 0.015(ig per reaction were set up and incubated as above. The 
transcription products were then used to set up triplicate PCR reactions for both 
VEGF and actin as before and products analysed using the GelDoc system.
_________ Reverse Transcription (VEGF)_________
RNA/reaction 
vg
Ac| Volume Mean Vol S.D 
counts x mrtf counts xrmtf
2 2271
2827
2049 2438 550
1 1412
1714
1427 1518 131
m 1203
930
1589 1241 232
0.25 722
831
487 680 129
0.125 162
261
169 197 42
0.0625 84
151
171 135 34
0.03125 68
124
59 84 27
0.015625 89
22
100 70 32
Table 22 Test of Linearity of Reverse Transcription Reaction by Serial Dilution (VEGF)
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Reverse Transcription (Actin)
RNA /reaction
ug
Adj Volume Mean Vd S,D 
counts x mm2 counts x mm2
2 (2715)
6010
5887 5949 87
3796
5656
5031 4828 688
0.5 3909
1362
4462 3244 1255
0.25 1430
2411
2377 2073 428
0.125 262
386
1210 619 394
0.0625 306
138
1132 525 404
0.03125 217
168
235 207 26
0.015625 236
207
49 164 77
Table 23 Test of Linearity of Reverse Transcription Reaction by Serial Dilution (Actin)
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Figure 19. Test of Linearity of Reverse Transcription Reaction by Serial Dilution (Actin)
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In both case a plateau effect was seen when the amount o f RNA in the reactions 
exceeded about 0.5pg. This was not unexpected since the manufacturer’s protocol 
for the reverse transcriptase recommends a maximum of 1 fig of RNA per reaction. It 
would be therefore more appropriate to look closer at the reactions with lower 
amounts o f RNA. These are plotted below.
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Figure 20. Linearity of Reverse Transcription Reaction (VEGF low range)
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Figure 21. Linearity of Reverse Transcription Reaction (Actin low range)
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With reactions containing less than 0.5|ig o f RNA per reaction, no plateau effect was 
demonstrated. It appears that in this range a linear relationship exists between the 
amount of RNA in the reaction and the amount of VEGF and actin cDNA generated.
6.4.5 Optimisation of the DNAase Protocol.
In the course o f screening RNA samples extracted from human tissue samples for 
DNA contamination it was found that occasionally a faint genomic band was seen in 
the actin PCR reactions. Experiments were therefore conducted to assess whether 
DNAase treatment o f the RNA samples would have any adverse effect on the 
subsequent RT-PCR reactions and to determine the best protocol for DNAase 
treatment.
One sample that had previously exhibited a genomic band in the actin PCR reaction 
and one that did not were used. Two micrograms of each RNA sample were diluted 
to 20pi. These samples were then split and half subjected to DNAase treatment. One 
microliter o f DNAase I (Gibco) and lp.1 of DNAase buffer (Gibco) were added to 
each sample to be DNAase treated. The tubes were then incubated at 25°C for fifteen 
minutes on the PCR block followed by heating to 65°C for ten minutes to denature 
the DNAase. The Gibco protocol recommends addition o f EDTA during the 
denaturation stage but it was hoped that this would not be necessary in order to avoid 
to the possibility that carry over might affect the conditions in the PCR reaction 
particularly be chelating magnesium. Each sample was divided following DNAase 
treatment. One half was subjected to reverse transcription as before whilst the other 
did not undergo reverse transcription. The halves o f the samples that had not been 
subjected to DNAase treatment were similarly split and one part subjected to reverse 
transcription. The final samples resulting from these divisions and treatments were 
then split and used in duplicate actin PCR reactions with the previously developed 
protocol. Products were analysed by gel electrophoresis.
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DNAase + RT Large smears on both samples.
DNAase - RT No contaminating bands.
No DNAase + RT Strong product bands on both samples
No DNAase - RT Contaminating 600 & 800 base pair bands
Table 24 Effect of DNAase treatment
The sample that previously exhibited contaminating DNA bands did so again. This 
was successfully eliminated by DNAase. However reverse transcription o f the 
DNAase treated samples resulted in a large smear, probably due to failure of 
deactivation o f the DNAase.
It appeared that more stringent methods were required to denature the DNAase either 
by the addition o f EDTA as suggested or using a higher temperature.
i
i
|
|
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6.4.6 Effect of different DNAase denaturing conditions on RT-PCR 
reaction yields for VEGF and Actin.
An experiment was designed to compare the product yields after reverse transcription 
and PCR when samples were prepared by different DNAase protocols.
The experiment used the tumour RNA sample with trace contaminating DNA which 
was used in the previous experiment. Samples were DNAase treated for fifteen 
minutes at 25°C and the DNAase was then deactivated by a ten minute incubation at 
either 65°C with addition o f lpl o f 20mM EDTA or 95°C with or without EDTA. 
Control samples with no DNAase treatment were also set up. Reverse transcription 
followed by PCR for actin and VEGF were carried out as before. VEGF and actin 
yields were compared between the DNAase free controls and the DNAase-treated 
samples using the various protocols.
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Actin
Adj Volume 
counts x mm*
_L
Mean 8»D
control 
(no DNAase 
or heat)
4676
3999
3874 4183 432
65 + EDTA 4660
4501
4330 4497 165
: l l l l l 3857
4893
4650 4467 542
95 + EDTA 4930
4780
4924 4878 85
VEGF
control 
(no DNAase 
or heat)
r
865
839
732 812 71
65 + EDTA
734
896
828 819 81
95
786
853
827 822 34
95 + EDTA
973
789
795 852 105
Table 25. Effect of DNAase denaturing conditions 011 RT-PCR Reaction Yield
There appeared to be little difference in the yield o f either VEGF or actin after PCR 
with DNAase treatment regardless o f which o f the protocols was used. In view of 
this it was felt that it would be reasonable to use the suppliers suggested protocol that 
involved denaturing the DNAase at 65°C in the presence o f EDTA. Since the 
reaction yield was so critical to quantification o f the PCR, it was felt advisable 
however to check whether the addition o f EDTA at this stage might alter the optimal 
magnesium requirement during the subsequent PCR.
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6.4.7 Optimisation of Magnesium Concentration in the PCR 
reaction for DNAase treated samples.
Given the concerns expressed above regarding the effect o f EDTA used in the 
neutralisation o f the DNAase on the magnesium concentration in the subsequent PCR 
reaction, re-titration of the amount of magnesium added to the PCR reactions was 
carried out.
T47D RNA was DNAase treated as before and the DNAase denatured by incubation 
at 65°C for ten minutes with addition o f l|il o f 20mM EDTA The treated RNA was 
then reverse transcribed as before. Actin PCR reactions were set up as before except 
that the concentration o f MgCb was titrated from 0.5mM to 3.5mM with triplicate 
reaction for each concentration. PCR were carried out for 25 cycles with a 60°C 
annealing temperature as before. Reaction yields were plotted against magnesium 
concentration.
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Mg Cone 
mM
Amount of Actin cDNA Product 
Rel Cone Mean S.D
0.5 0
0
0 0 0
1 4392
4467
4662 4507 139
1.25 5901
6077
5615 5864 233
1.5 4299
4167
5974 4813 1007
1.75 4393
4476
5073 4647 371
" ■ 2 ] 2711
3715
3543 3323 537
2.25 687
2053
760 1167 768
2.5 1609
534
1495 1213 591
3 1320
901
735 985 301
3.5 1736
950
200 962 768
Table 26. Optimisation of PCR Mg2+ concentrations for DNAase treated samples
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Figure 22. Optimisation of PCR Mg2+ concentrations for DNAase treated samples
The peak reaction yield appeared to occur at a magnesium concentration o f around 
1.25-1.5 mM. It appeared therefore that using DNAase and denaturing it with EDTA 
did not affect the magnesium requirement in the PCR reaction. No change in this 
protocol was therefore required.
125
Chapter 7. Analysis o f RNA from Human Breast 
Samples
7.1 Introduction
The aim of the work in the preceding chapter was to develop an assay that could be 
used to measure the amount o f VEGF RNA in breast tumours and other breast tissue 
samples.
This chapter describes the work carried out with samples derived from human breast 
tissues. The first section o f the work described in this chapter was carried out at an 
early stage in the development o f the assay. At this stage the reverse transcription and 
p-actin PCR reactions had not been optimised and tested. The optimal number of 
cycles for the VEGF PCR assay had also not been finalised. Up to that point, all of 
the development work had been carried out on mRNA extracted from a cell line. It 
was not known whether the technique being developed could detect VEGF mRNA in 
material from human tissue samples and how the amount o f mRNA in this material 
would compare with the cell lines. The availability of a number o f samples o f cDNA, 
which had been prepared from RNA from normal human breast and breast tumours, 
gave the opportunity to determine whether the use of this assay was feasible.
The next section o f the work in this chapter was carried out once the development of 
the assay appeared complete. Archival material that had been stored in 1989 was 
used. It was hoped that the use of this early material would give the longest possible 
patient follow-up. Whilst the samples used in this part o f the work proved free of any 
contaminating DNA other samples subsequently tested showed traces o f P-actin DNA 
when screened prior to analysis. The use o f DNAase treatment was therefore 
investigated prior to analysis o f further samples. This treatment was then used on the 
material subsequently analysed. The later material analysed was derived from tissues 
stored in 1993. In the interim, changes had been implemented in the method of 
storage of breast tumour samples in the department and it was hoped that the RNA in 
these samples would be better preserved.
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7.2 Methods
7.2.1 Preliminary application the technique to cDNA samples from 
human tumours.
Prior to optimisation and testing of the reverse transcription and actin PCR, several 
cDNA samples prepared by reverse transcription o f RNA from human breast tissues 
had been made available by Dr V. Speirs o f the University o f Hull. These were used 
to verify the feasibility o f using the VEGF PCR assay to study human material
There were six cDNA samples derived from non-malignant breast tissue (obtained 
from reduction mammoplasties) and six samples from ductal carcinomas o f the breast. 
These had been frozen in liquid nitrogen prior to extraction o f RNA with TRIzol. 
After RNA estimation by spectrophotometry lpg samples o f total RNA had been 
reverse transcribed using Superscript II reverse transcriptase in accordance with the 
manufactures protocol.
PCR reactions were set up in triplicate for each sample. Simultaneously, reactions 
were prepared containing serial dilutions of T47D cDNA (lul to 0.008|il o f cDNA 
per reaction). PCR reactions were set up containing 2 units o f Taq, 0.8pmol o f dNTPs 
and lOOng of each primer per reaction, with a MgCfe concentration o f 1.5mM. lpl of 
the cDNA from each sample was placed in each reaction tube. The PCR reactions 
were run for 30 cycles. Two gels were required to accommodate the samples. 20pl 
from each reaction of serially diluted T47D cDNA was run on each gel to allow the 
plotting o f a standard curve for that gel. The remaining triplicate samples were 
divided between the two gels. The amount o f T47D cDNA present in the sample 
relative to the amount present in lpl of cDNA derived from T47D RNA was 
estimated by comparison with the standard curve for that gel, using the GelDoc 
system.
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7.2.2 Non-Quantitative PCR of cDNA from Human Breast Tissue 
Samples.
An experiment was set up to determine whether more o f the samples used in the 
previous experiment would show VEGF expression given further amplification. 
Reaction conditions were the same as used in the above experiment. Duplicate 
reactions were set up for each sample and PCR carried out as before but for 35 
cycles instead o f 30. It had already been determined that with this number of 
cycles, increasing the amount o f cDNA template did not necessary result in a 
proportional increase in the amount o f product. Therefore the reaction was not 
quantifiable after this amount o f amplification. No measurements were therefore 
made from the gel bands and only an approximate comparison o f the samples by 
visual assessment was made.
7.2.3 Examination of Archival Human Breast Tumours with the 
Optimised PCR Based Assay
Initially an attempt was made to analyse RNA from archival breast tumours that had 
been stored in liquid nitrogen in 1989 and consequently had a long-term follow up 
data available. Samples o f tumour and adjacent apparently uninvolved breast had 
been stored in the Department of Surgery, Western Infirmary, Glasgow at that time by 
wrapping 2-3 cm diameter pieces in aluminium foil after surgical excision and rapidly 
placing them in liquid nitrogen, where they had remained. Working on a liquid 
nitrogen cooled tray to prevent thawing, pieces were removed from these blocks with 
bone nibblers. These pieces were then ground to a fine powder and subjected to 
TRIzol RNA extraction.
Five pairs o f samples o f tumour and adjacent breast were initially prepared. RNA 
concentrations were estimated by ultraviolet spectrophotometry. One microgram of 
each RNA sample was run on an RNA gel to determine which showed clear ribosomal 
bands. The methods for RNA gel electrophoresis have previously been described in
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chapter 3. The quality o f these samples appeared generally poor but the best three 
pairs were chosen for further analysis.
The samples were then screened for genomic DNA carryover by placing 0.3pg of 
RNA into VEGF and Actin PCR reactions as used previously used for analysing the 
reverse transcription products. Despite there being over six times as much of the 
original RNA solution as would normally be carried over into the PCR reactions, no 
product was detected in any o f the VEGF or actin reactions.
Reverse transcription reactions were set up using the protocol optimised in the 
previous section with 0.5pg o f each RNA sample in each reaction. A large batch of 
T47D RNA was prepared by TRIzol extraction to provide a standard. Its 
concentration was determined by UV spectrophotometry and it was screened for 
contaminating DNA by PCR. Two reverse transcription reactions containing 0.5pg of 
the T47D RNA were set up.
The products o f the reverse transcriptions were made up to 100 pg with water. PCR 
reactions for VEGF and actin were set up for each sample using the protocols 
previously optimised. Triplicate reactions were set up from each reverse transcription 
reaction with 10 pg of reverse transcription product added to each. Products were 
electrophoresed on agarose ethidium bromide gels and these were analysed using the 
GelDoc system as previously described. Standard curves for VEGF and actin were 
produced by linear regression o f the measurements from the serial dilutions T47D by 
the GelDoc software. Relative concentrations of the sample mRNA species calculated 
by comparison with this. To correct for variations in total mRNA between samples, 
results for each sample were then expressed as a VEGF/Actin ratio.
Case notes were extracted in December 2000 to obtain details o f adjuvant therapy and 
the result of follow up. The total length o f follow up was calculated from the number 
of days between surgery and the last recorded surgical review.
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7.2.4 Examination of cDNA from 1993 Samples
Samples o f tumour and adjacent breast from eight patients who had undergone 
surgical treatment of breast cancer in the Western infirmary during 1993 were 
extracted from the tumour bank. These samples had been cut into fragments on a 
liquid nitrogen cooled tray then immediately put in vials. These vials were placed in 
liquid nitrogen. It was hoped that this would result in more rapid and uniform 
freezing than had occurred in the older samples which had been frozen in large blocks 
wrapped in aluminium foil. A sample of tumour from an axillary lymph node was also 
available for one o f these patients and was also processed.
Tissues were ground to a powder using equipment cooled with liquid nitrogen and the 
RNA extracted with TRIzol as before. Initial screening o f these samples showed faint 
genomic actin band in some. It was therefore necessary to carry out DNAase 
treatment. The optimisation of protocols for this has been discussed in the preceding 
chapter. DNAase treatment was carried out for fifteen minutes at 25° C then lpl of 
20mM EDTA added and the DNA denatured by heating to 65°C for ten minutes. The 
T47D cell line control RNA was also DNAase treated. The treated samples were then 
checked for residual DNA contamination by VEGF and actin PCR reactions as 
before. No evidence of any residual contamination was seen.
As previously described, 0.5fig o f each tissue RNA sample was reverse transcribed as 
was the T47D control RNA. The products of the reverse transcription were diluted 
to lOOpl with water and four VEGF and four actin PCR reactions each containing 
lOfil o f the diluted RT product set up from each. VEGF and actin PCR reactions 
containing serially diluted T47D reverse transcription product were also set up, as has 
been previously described, to create standard curves. Products were analysed by gel 
electrophoresis and relative VEGF and actin concentrations for each sample 
calculated by comparison with the T47D standard curves by linear analysis using the 
GelDoc software.
Case notes were examined in December 2000 to obtain follow-up information as 
before.
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Comparisons of VEGF expressions between different groups pathological and 
outcome groups were made using the Mann-Whitney rank sum test. Relationship 
between tumour size and VEGF expression was examined by Pearson correlation. 
Statistic were calculated using the StatsDirect v2.0.1 statistical package (StatsDirect 
Ltd)
7.3 Results
6.3.1 Preliminary application the technique to cDNA samples from 
human tumours.
Standard Curve
1st get 2nd gel
Amount of cDNA Rel. vof of band Rel. vot of band
per reaction (uf) counts x mm 2 counts x mm 2
•T:- 1626 1586
0.5 858 985
0.25 383 506
0.125 177 278
0.0625 99 187
0.0313 64 53
0.0156 27 59
0,0076 0 0
Table 27. Standard curves for gels-preliminary application of RT-PCR technique to
tissues samples.
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Figure 23. Standard curves for gels-preliminary application of RT-PCR technique to
tissues samples.
The above plots suggest a linear relationship between the starting amount o f T47D 
cDNA and the amount o f product.
In three reduction mammoplasty specimens and three ductal carcinoma specimens, no 
product was detected. The amount o f product obtained with the remaining samples is 
shown below. The amount o f product obtained for each reaction was related to the 
amount obtained from with each was related to that obtained from T47D using the 
standard curves and a mean relative signal and standard deviation calculated for each 
sample. Sample designations are those ascribed by the Hull laboratory.
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Type of Sample Designation Amount of Product VEGF signal Mean Relative S.D
Rei. vol of ba nd relative to T47D signal
Reduction R6 169 0.10
Mammoplasty 219 0.13
242 0.15 0.13 0.02
Reduction R195 193 0.1
Mammoplasty 166 0.0838
177 0.0903 0.09 0.01
Reduction R5 100 0.0429
Mammoplasty 186 0.0957
183 0.0937 0.08 0.03
Lumpectomy C15 128 0.0599
98 0.0416
34 0.0019 0.03 0.03
Mastectomy M3 49 0.011
60 0.0178
8 0.01 0.00
Mastectomy M18 304 0.1687
232 0.124
256 0.1394 0.14 0.02
Table 28. Estimation of relative VEGF expression in tissues samples-preliminary
application
This experiment has demonstrated that it is possible to detect VEGF in samples of 
cDNA produced by reverse transcription of RNA from human tumour material. 
There was a large variation between samples in the amount o f VEGF product 
obtained but no obvious association between the nature o f the sample and the amount 
of VEGF.
The linearity o f the reverse transcription reactions used to prepare these samples had 
been had not been verified. It was assumed that the same amount o f mRNA was 
present in all o f the samples based on standardisation o f the amount o f total RNA 
used in the reverse transcription reactions by spectrophotometry. However, no 
internal standards such as p-actin or GAPDH were included.
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6.2.2 Non-Quantitative PCR of cDNA from Human Breast Tissue 
Samples.
-------------------------------- -------------- --------------------------
Reduction Mammoplasty Samples
Ductal Carcinoma Samples
1 2 3 4 5 6
Reduction Mammoplasty 
Samples
1: R1 
2: R195 
3: R6 
4: R5 
5: R12 
6:R15
Ductal Carcinoma Samples
4: M18
6: C15
Figure 24. Gel Electrophoresis o f RT-PCR Amplified VEGF from Reduction 
Mammoplasty and Ductal Carcinoma Specimens.
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It can be seen that after 35 cycles, a band consistent with the VEGF PCR product was 
amplified from the cDNA derived from all o f the reduction mammoplasty tissue and 
all but one o f the tumour samples. Furthermore the bands obtained from some o f the 
reduction mammoplasty tissue were o f a similar size to those obtained from the 
tumour samples. The demonstration o f the expression o f VEGF RNA by benign 
breast tissue suggested that to investigate differences in expression o f VEGF between 
benign and malignant breast tissue, an assay that allows quantitative comparison was 
needed.
Prior to carrying out any further work on human material, improvements were 
required to the assay system. The conditions for the reverse transcription assay were 
optimised and the linearity of this stage o f the reaction tested. A PCR assay for 
P-actin was optimised to provide an internal standard. Further work was carried out 
on the VEGF PCR reaction to improve its sensitivity by increasing the amount of 
amplification that could be achieved whilst still maintaining a linear relationship 
between template and product quantities. This work has been described in chapter 6 
above.
6.3.3 Examination of Archival Human Breast Tumours with the 
Optimised PCR Based Assay (1989 patients)
Pathological and clinical data for these patients is shown in the table below. 
Photographs o f the gels produced by electrophoresis o f the PCR products and the 
results o f Geldoc analysis o f these gels is also shown.
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Figure 25. Gel Electrophoresis of RT PCR products-1989 patients
VEGF Actin VEGF/
Sample Ret. Cone. Mean S.D Rel. Cone. Mean SJQ Actin
Ratio
1
Adjacent
Breast
0.225
0.237
0.241 0.234 0.008
0.271
0.300
0.600 0.390 0.182 0.600
1
Tumour
0.011
0.049
0.030 0.030 0.019
0.081
0.102
0.163 0.115 0.043 0.261
2
Adjacent
Breast
0.259
0.261
0.259 0.259 0.001
0.753
0.562
0.580 0.632 0.105 0.411
2
Tumour
### ### ###
0.064
0.097
0.063 0.075 0.020 m
3
Adjacent
Breast
0.101
0.123
0.110 0.111 0.011
0.651
0.400
0.453 0.501 0.132 0.222
3
Tumour
0.073
0.081
0.046 0.066 0.018
0.282
0.121
0.166 0.189 0.083 0.351
### Bands not visible on gel
Table 30. Semi-quantitative analysis of VEGF expression-1989 patients
Semi Quantitative Analysis of 
VEGF Expression
C  0.8 T -
o  0.6 - 
-  0 .4 -
<D 0.2 -  
UJ>  o 4-
Adj N-ve N+ve Adj.Adj.t lobular
Ductal ductal
Figure 26. Semi-quantitative analysis of VEGF expression-1989 patients
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6.3.4 Examination of cDNA from 1993 Samples
RNA was extracted from tumour and adjacent breast tissue obtained from patients who 
had undergone surgery in 1993 as described above. These samples had been frozen and 
stored under better conditions than the previous samples and it was hoped that the RNA 
would be better preserved.
Clinical and pathological data for these patients whose tumours were analysed in this 
study is shown below as are the results of the semi- quantitative RT PCR on the 1993 
patient samples are shown below. As before, relative concentrations of VEGF and actin 
were used to calculate a VEGF/actin ratio to compensate for variations in readable 
mRNA between samples. A further ratio was obtained by dividing the VEGF/actin ratio 
for each tumour by the VEGF/actin ratio for the adjacent breast.
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Adjacent b reas t
0.098
0.161
0.251
0.164 0.169 0.063
0.003
0.011
0.003
0.003 0.005 0.004 35.309
A
t u m v f
1.089
1.870
1.519
1.963 1.610 0.397
0.009
0.008
0.009
0.004 0.007 0.002 215.405
%
Breast
0.000 
0.000 
0.000 
0.000 0.000
0.000 
0.000 
0.000 
0.000 0.000 na
2
Tumour
0.382
0.271
0.604
0.264 0.380 0.159
0.088
0.056
0.079
0.074 0.074 0.013 5.106
2
t y t y h t i o t e
0.905
0.973
0.928
0.849 0.914 0.051
0.223
0.001
1.344
1.097 0.666 0.654 1.371
3
AtgaeewBresitf
0.000
0.000
0.000
0.000 0.000 0.000
0.000
0.000
0.000
0.000 0.000 0.000 0.000
3
Tumo(ir
1.949
1.684
0.132
1.603 1.342 0.820
0.074
0.128
0.103
0.073 0.094 0.026 14.206
4
Acjiaeerit&taast
0.660
0.811
1.198
0.443 0.778 0.318
0.043
0.044
0.008
0.015 0.027 0.019 28.575
A
Temow
0.957
0.803
0.810
0.743 0.828 0.091
0.045
0.045
0.033
0.037 0.040 0.006 20.640
$
4c#a$«*-Br»sst
1.387
2.821
1.680
2.447 2.084 0.664
0.171
0.193
0.233
0.233 0.207 0.031 10.058
a
Tumour
0.000
0.864
0.896
0.802 0.640 0.429
0.000
0.000
0.000
0.000 0.000 0.000 na
3
Adjacent Breast
2.440
2.888
0.515
1.494 1.834 1.054
0.104
0.102
0.100
0.060 0.092 0.021 20.023
$
Tumour
3.200
2.214
3.180
3.158 2.938 0.483
0.119
0.142
0.163
0.177 0.150 0.025 19.556
f
Msaer# Breast
0.113
0.124
0.078
0.125 0.110 0.022
0.068
0.070
0.055
0.032 0.056 0.017 1.956
7
T«W W
2.110
0.800
0.013
1.915 1.209 0.984
0.300
0.261
0.150
0.233 0.236 0.064 5.125
a
A ccen t'B reast
0.132
0.067
0.105
0.034 0.084 0.043
0.000
0.000
0.000
0.000 0.000 0.000 na
5
Tumour
0.173
0.106
0.110
0.002 0.098 0.071
0.113
0.117
0.115
0.073 0.104 0.021 0.937
Table 37-Semi-quantitative analysis of VEGF expression-1993 patients
Tumour Tumour Tumour to 
VEGF/Actin Adj. Breast ratio
1 215.40 6.10
2 5.11
3 14.21
4 20.64 0.72
5
6 19.56 0.98
7 5.12 2.62
8 0.94
Table 32 Semi-quantitative analysis of VEGF expression in 1993 
Patients- comparative ratios
6.4 D iscussion.
With the samples from the 1989 patients it was possible to demonstrate VEGF expression 
in two of the ductal carcinomas and adjacent breast. No VEGF bands were visible in the 
sample from a lobular tumour. It is interesting that the sample from the node negative 
tumour showed VEGF expression at a lower level than the surrounding breast whilst the 
node positive tumour showed a higher level than the surrounding breast. However it 
would be inappropriate to draw conclusions from this on the basis of two samples. This 
is particularly true since the quality o f RNA extracted from these samples was poor. It 
was decided that samples that had been frozen more recently would be more useful for 
further work. These more recent samples had been cut into much smaller pieces before 
being placed in liquid nitrogen and had therefore frozen faster and more evenly.
In the 1993 samples, VEGF was detectable in RNA from all of the tumour samples and 
from six samples o f adjacent breast. The two samples of adjacent breast that failed to 
yield detectable VEGF did not show any product with the actin PCR A further sample 
of adjacent breast that yielded VEGF PCR product failed to yield any actin. This 
appeared therefore to be a reflection of the poor quality of the mRNA in these samples 
despite standardization o f the total RNA in the reaction by spectrophotometry. 
Surprisingly, one o f the tumour samples and one of the samples of adjacent breast that 
exhibited product in the VEGF PCR reaction failed to yield any actin product on any of
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the replicate PCR reactions, despite the actin and VEGF PCR reactions being carried out 
on products from the same reverse transcription reaction.
There was a considerable difference in the VEGF/actin ratios between the tissue samples 
derived from patients who underwent surgery in 1989 or 1993. The mean of the VEGF 
products measured in the 1993 group was almost twice that of the 1989 group whilst the 
mean of the actin products in the 1993 samples was a third of that of the 1989 samples. 
The only difference in the analysis of the two groups of samples was that the 1993 RNA 
samples were treated with DNAase prior to reverse transcription. The 1989 samples 
were screened for contaminating DNA prior to use and none was demonstrated. It has 
been shown that the DNAase treatment does not affect the yield of products from either 
the actin or VEGF RT-PCR Certainly even within each group there were large 
differences in the yield of actin between different tissue samples suggesting that there 
were differences in the quantity of intact mRNA capable of being reverse transcribed. 
This occurred despite standardization of the amount of total RNA in the samples by 
spectrophotometry. The difference in actin yield between the 1989 and 1993 group was 
statistically significant (p<0.0001). This suggested that either the RNA in the two 
groups of samples has been preserved to a different extent or that there is an overall 
difference in the efficiency of the PCR reactions between the two groups. For this 
reason, the data from the two groups of samples could not be assessed together.
Of the eight patients from the 1993 group, pathological data was available for all. All 
samples were ductal carcinoma though one of these was arising with in a phyllodes 
tumour. Five of the tumours had positive lymph nodes. Follow up data was available for 
six of the patients. Mean length of follow up was 53 months (range 23-77 months). 
During this time three out of six patients developed distant recurrence of their tumours 
and subsequently died. One elderly patient had not been followed up and a further had no 
case notes on file.
Usable VEGF quantification (VEGF/actin ratio) was obtainable for seven of the tumour 
samples and five of the samples of adjacent normal breast.
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A statistically significant difference in between pre and postmenopausal patients in VEGF 
expression (VEGF/actin ratio) could not be demonstrated in either the tumours or 
adjacent breast (p=0.4 and p=0.2). No significant difference could be demonstrated 
between VEGF expression in node negative or positive tumours (p=0.85) or between 
tumours of high histological grade (3) or those of low grade (1&2) (p=0.86). There was 
no significant correlation between tumour size and VEGF expression (r=0.23 p=0.59).
There was no significant difference between VEGF expression in normal breast and 
tumours (median 20 v 14.2 p=0.64, 95.2% Cl = -18.6 to 23.4.) Whilst patients who 
developed distant recurrence had a mean VEGF/actin ratio higher than those and those 
who did not the small number of samples meant that the possibility that this was due to 
chance could not be excluded, (median 5.13 v 17.42, p=0.4).
It has been demonstrated that VEGF mRNA is stabilized by hypoxia and therefore 
accumulates in hypoxic cells. It is likely that surgically excised tumours are subjected to 
a period of hypoxia. This starts during mobilisation of the tumour or entire breast as the 
blood supply is progressively withdrawn. There is then a period between the tumour 
being removed from the patient and placed in liquid nitrogen during which it is hypoxic. 
It is possible that the time taken to surgically remove the tumour and the transport and 
processing times may influence the amount of VEGF mRNA in the tumour. The 
protocols regarding tumour processing in place at the Western Infirmary were such that 
tumour material could not be removed for research purposes before the specimen had 
been processed in the pathology department. There had therefore been some delay in 
freezing of all of the material in the tumour bank. It is notable that if all of the tissues, 
benign and malignant from mastectomy specimens are compared with those from wide 
local excision (lumpectomy) specimens, a statistically significant difference exists (median 
20.02 v 1.19 p=0.026). When only tumours from mastectomy and lumpectomy specimens 
are compared the difference does not reach statistical significance (medianl9.66 v 3.03 
p=0.19). The lumpectomy tumours were smaller and of lower grade. It is not clear 
whether this represents a true difference in the biology of the tumours or a difference in
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the conditions prevailing in the tumour, particularly cellular hypoxia during and 
immediately after surgery. Further work is needed to determine the changes that occur in 
tissue VEGF mRNA levels in tissue samples after devascularisation.
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Chapter 8. Final Discussion
When this study was embarked upon in 1994, there had been extensive debate in the 
literature over the preceding three years about the significance of microvessel density, a 
histological measure of angiogenesis in breast cancer. As discussed in the introduction, 
most workers found that a high microvessel density predicted for poor outcome in breast 
cancer. Whilst potentially useful, the assessment of microvessel density was fraught with 
problems of observer variability and was a rather time consuming technique for routine 
clinical pathology. Furthermore it relies on having a sufficiently large block of tissue for 
preparation of suitable tissue sections and could therefore only be assessed following 
surgical removal of the tumour.
Given the suggestion from measures of microvessel density that angiogenesis could 
predict for tumours with a worse prognosis, it may be useful to have a technique that 
would identify these tumours with a high potential for angiogenesis. Ideally, if this 
phenotype could be identified prior to surgery, it would then be possible to assess 
whether alterations in the management of these patients such as neo-adjuvant chemo- 
radiotherapy might alter their outcome. Therefore a technique that could be applied to 
small amounts of tissue was potentially advantageous.
In 1989, Napoleone Ferrara had described Vascular Endothelial Growth Factor (VEGF). 
This seemed to be potentially the most important angiogenic factor yet described. It had 
been reported that in tumours of the central nervous system and kidney, VEGF was 
present at higher levels that in the tissue of origin. There had not been any report of 
VEGF expression in breast tumours. However, if any single factor was able to identify 
those breast tumours with a high angiogenic potential, VEGF seemed to be the most 
promising. This study was therefore designed to determine whether VEGF could be 
identified and quantified in breast tumours.
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The few studies that had been published at that time reporting VEGF expression in 
tumours had used either immunohistochemistry or in situ hybridisation. Both of these 
techniques on their own have inherent problems. Immunohistochemistry identifies that a 
substance is present within a tissue. As previously stated, VEGF has several forms which 
bind to the tissue substrate to a varying extent. Immunohistochemistry will give an 
indication of the amount of VEGF bound to tissue components. This does not 
necessarily reflect which cells in the tissue are actually producing it or even how much is 
being produced since the soluble forms may be lost from the tissue. In situ hybridisation 
identifies the expression of mRNA by cells. This has the advantage of identifying the 
cells that are probably producing the substance and since the RNA does not escape from 
the cells, it is not influenced by differences in tissue binding. However, the expression of 
mRNA by a cell does not necessarily prove that it is actually producing the protein. The 
two techniques are therefore complementary. Since these techniques had been reported 
as able to identify VEGF in tissues, attempts were made in this work to employ them. It 
should be noted however that both of these techniques have the disadvantages previously 
noted with microvessel counting. They both employ sections of tissue though could 
potentially be applied to cytological preparations. Both techniques require a visual 
analysis of the stained slides and an assessment of the degree of staining.
A technique that could rapidly give an estimate of VEGF expression from a very small 
sample of tissue and which was not subject to observer variations would be ideal. RNA 
in tissue samples can be measured by Northern blotting but this requires relatively large 
amounts of tissue. The polymerase chain reaction (PCR) offered the potential to identify 
VEGF in tiny samples of tissue. The initial work in this study to develop a VEGF 
riboprobe had demonstrated that VEGF mRNA could readily be amplified by RT-PCR. 
PCR was however regarded as largely a qualitative technique. Methods for using it 
quantitatively have however have been described and these have been discussed already 
in the introduction to chapter 6. Whist competitive techniques have been described their 
use requires multiple reverse transcription and PCR reactions. This greatly increases the 
amount o f template RNA required as well as the assay cost. These techniques are 
therefore less suitable for application to routine clinical use. It was felt that with close
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attention to optimisation of assay conditions and careful verification of the relationship 
between template and product that a simpler PCR based system could be employed.
The development of this assay is described in this work. A PCR based assay has been 
developed which yields a linear relationship between the amount of mRNA in a starting 
sample and the relative amount of VEGF product measured by computer analysis of the 
PCR products. The assay system includes an internal standard in the form of p-actin to 
control for variations in the quantity and quality of mRNA contained in the samples and 
any differences in the efficiency of reverse transcription between samples. The assay is 
sufficiently sensitive to allow estimation of VEGF using only 0.5pg of total RNA from 
each tissue sample and could be used with even smaller amounts of RNA. It gives an 
opportunity to study VEGF expression in tissues in either a research or clinical context 
where the amount of tissue available for study is restricted. It could be applied to small 
amounts of archival material or to small biopsy samples such as fine needle aspirates from 
patients.
After the completion of this work, Anan et al [87] in Japan described a very similar semi- 
quantitative PCR based system. They too compared VEGF and p-actin amplified by 
PCR from tumour RNA with the same products amplified from a standard sample of 
RNA from a breast cancer cell line. The main difference in methodology was that they 
initially employed a radioactive label and southern blotting to quantify the product bands 
rather than direct computer analysis of the gel used in this study. The method described 
in this study eliminates the safety and a logistical problem associated with the use 
radioactivity and eliminates a time-consuming blotting stage. In a subsequent publication, 
the same group used photographs of the gels scanned on a flatbed scanner and analysed 
by computer [88], They showed that the results obtained with this technique correlated 
closely to their radioactive method.
Among the aims of the in the present study, it had been intended to compare VEGF 
measurements from tumour samples with the tumour microvessel counts and to assess the 
feasibility of using the assay on tumour samples abstained by fine needle aspiration. Time
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did not permit the achievement of these objectives in this study. Annan et al however did 
use the semi-quantitative PCR assay for this purpose [87, 88], They demonstrated a 
correlation between high microvessel density and increased expression of VEGF mRNA 
and a correlation between VEGF mRNA estimations from FNA samples and from larger 
samples of the tumour.
As previously stated, the transcription and stability of VEGF RNA in cells is affected by 
tissue hypoxia. With any surgically excised material there will be a period between the 
tissue being deprived of its blood supply and the complete cessation of metabolism by 
fixation or freezing. With the material used in this study, this study had been 
compounded by the transfer of the tissue to the pathology department prior to it being 
available for freezing. The effect of this delay on the VEGF mRNA concentration in the 
cells is unknown. Further work to determine the change in VEGF mRNA conditions in 
devascularised tissues would be valuable.
Comparisons were made between tumours and the histologically normal breast adjacent 
to the tumour. It has however been found previously [17] that apparently normal tissue 
from tumour bearing breast is more angiogenic in vivo than tissue from breasts without 
tumours. Therefore, the lack of a demonstrable difference between the tumours and 
adjacent breast tissue may be at least partly due to the breast tissue adjacent to the 
tumours producing more VEGF than would be produced by normal breast tissue.
Due to time constraints, the assay has only been used to analyse a small number of 
archival tissue samples. No statistically significant associations were seen between the 
expression of VEGF in these samples and any of the pathological or outcome variables 
examined. The statistical power of the study however is not sufficient to exclude the 
existence of such associations. Subsequently several researchers have found that high 
VEGF expression in breast carcinomas predicts for poor outcome. The results of these 
studies have been outlined in the introduction.
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Attempts to demonstrate VEGF by immunohistochemistry proved unsuccessful despite 
the use of antigen unmasking techniques such as microwaving and trypsin digestion. 
Although demonstration of VEGF by immunohistochemistry has been reported [77] 
subsequent discussions with other workers has revealed that they too have had difficulty 
demonstrating VEGF by this method. It may be that the tissue fixation influences the 
success of this technique but staining was also not seen with the frozen sections and 
cytological material used. It was felt that, with the antibodies available at the time of this 
study, immunohistochemistry was not a viable method for assessing VEGF expression.
In this study an RNA riboprobe was produced by cloning of part of the first exon of the 
VEGF cDNA into an expression vector and transcription of a digoxigenin labelled 
antisense mRNA molecule. Despite verification of the sequence of the cloned vector, 
attempts to use this probe to detect VEGF mRNA in either northern blots or in situ 
hybridisation proved unsuccessful. Subsequently, a sample of plasmid DNA cloned with 
VEGF RNA was obtained from Genentec. However it was felt that the PCR based assay 
held greater potential and attempts to detect VEGF RNA using a riboprobe has not as yet 
been pursued further by either in situ hybridisation of northern blotting.
Commercial kits have now become available to detect VEGF protein by enzyme linked 
immunoseroassay (ELISA). These kits allow rapid measurement of VEGF protein and 
have contributed to the rapid expansion of the literature regarding VEGF in cancer in the 
last few years. There must be some caution regarding the measurement of VEGF protein 
in tissues given the variable binding of different forms of the protein to the extracellular 
matrix. The technique has however facilitated the rapid processing of large numbers of 
patient samples and yielded data on links between VEGF expression and clinical outcome 
in cancer. It is also possible that measurements of VEGF in the blood of patients with 
breast cancer may yield prognostic information. Lantz et al [122] have demonstrated a 
correlation between pre-operative serum VEGF and microvessel density in 46 breast 
cancer patients. The prognostic value of measurements of circulating VEGF are as yet 
unknown.
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RT-PCR based techniques such as that described here cannot compete with ELISA in for 
economy or ease of use. However, when only small amounts of material such as fine 
needle aspirates or small biopsies are available to study, the amplification inherent in this 
technique means that it may prove valuable. The ability to study the production of 
individual splice variants of VEGF by using different PCR primers also contributes to its 
potential usefulness.
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Appendix.
Comparison of the VEGF sequence derived with each sequencing primer in the sequenase 
reaction with the published VEGF sequence (Section 2.2.15)
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